Methods to enhance car t cell persistence and expansion
Patent Information
- Application Number
- PCT/US2026/018769
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-11
- Filing Date
- 2026-03-11
- Publication Date
- 2026-11-19
AI Technical Summary
Current CAR T cell therapies for cancer treatment are limited by poor persistence and expansion due to challenges in identifying effective lymphocyte modifications that can function optimally within the solid tumor microenvironment, and existing in vitro CRISPR/Cas9-based approaches are inadequate for in vivo applications.
An in vivo genome-scale CRISPR knockout screen identifies key gene targets such as ATXN7L3 and USP22 for modifying lymphocytes, combined with strategies like IL-2 or IL-15 expression to enhance CAR T cell persistence and expansion, and the use of orthogonal IL-2/IL-15 signaling systems to regulate lymphocyte function.
Enhances CAR T cell persistence and expansion, improving their therapeutic efficacy against various cancers by overcoming limitations in in vivo tumor environments and restoring IL-2 production, thereby boosting antitumor immunity.
Abstract
Description
[0001] DESCRIPTION
[0002] METHODS TO ENHANCE CAR T CELL PERSISTENCE AND EXPANSION PRIORITY CLAIM
[0003] This application claims benefit of priority to U.S. Provisional Application Serial No.
[0004] 63 / 700,125, filed March 11, 2025, the entire contents of which are hereby incorporated by reference.
[0005] REFERENCE TO A SEQUENCE LISTING
[0006] This application contains a Sequence Listing XML, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said Sequence Listing XML, created on March 11, 2026, is named CHOPP0089WO.xml and is 1,933 bytes in size..
[0007] BACKGROUND
[0008] I. FIELD
[0009] The present disclosure relates generally to the fields of molecular biology, oncology, medicine and immunology. More specifically, it provides engineering of lymphocytes, particularly chimeric antigen receptor (CAR) T cells, to improve their action as therapeutic in treating cancer.
[0010] II. RELATED ART
[0011] Cancer is the second leading cause of death in the world, accounting for one in six deaths. Current treatment options, including surgery, chemotherapy, radiotherapy and target therapy, can lead to complete remission. However, most patients still do not respond or experience tumor progression after therapy, calling for new therapeutic strategies in cancer treatment. Adoptive chimeric antigen receptor (CAR) T cell therapy has shown durable complete remissions in leukemia and lymphoma, thus revolutionizing clinical guidelines in hematologic malignancies.
[0012] Unfortunately, limited CAR T cell persistence is a key factor restricting therapeutic responses. Unbiased approaches such as genome-scale CRISPR screening have identified several pathways to enhance cell persistence. These screens, however, have mainly utilized in vitro approaches, which do not fully recapture a solid tumor microenvironment. To date, an in vivo genome-scale CRISPR knockout (KO) screen in human CAR T cells has yet to be
[0013] 1
[0014] 4897-8742-6199, V 1published, in part due to challenges with standard CRISPR / Cas9-based approaches. The ability to identify lymphocytes and CAR T cells that will provide the most robust responses would therefore be of great value in the more efficient implementation of this powerful therapeutic tool.
[0015] SUMMARY
[0016] The present disclosure provides a method of modifying a lymphocyte or lymphocyte population comprising (a) providing a lymphocyte or lymphocyte population; and (b) modifying said lymphocyte or lymphocyte population to decrease or block expression of the gene products of (i) either or both the ATXN7L3 and / or USP22 genes, (ii) one or more of the other genes in FIG. 3E, and / or (iii) TADA1, SUPT20H, and / or TAF5L. Modifying may comprise gene editing of cither or both ATXN7L3 and / or USP22 genes. Gene editing may comprise use of CRISPR, TALENs, or zinc-finger nucleases. The lymphocyte or lymphocyte population may be a T cell or T cell population, such as a T cell or T cell population that is or comprises a regulatory T cell, a helper T cell, a cytotoxic T cell, a yδ T cell(s), an NK cell, a CAR T cell, a TCR-engineered T cell, a TIL or engineered TIL, an engineered version of any of the foregoing, or a population thereof. The method may be such that only the USP22 gene or the ATXN7L3 is modified, or such that both the ATXN7L3 and USP22 genes are modified. The lymphocyte or lymphocyte population may be screened for the presence of one or both gene editing events. Modifying may comprise gene editing (a) one or more of the other genes in FIG. 3E, and / or (b) TADA1, SUPT20H, and / or TAF5L. In another embodiment, there is provided a lymphocyte or lymphocyte population prepared according to the methods described herein.
[0017] The method may further comprise expanding the lymphocyte or lymphocyte population after step (b). The method may further comprise genetically modifying a lymphocyte or lymphocyte population to constitutively or inducibly express IL-2, IL-7 or IL- 15 or receptors for the same, or to express IL-2, IL-7 or IL- 15 or receptors for the same at a level greater than prior to modifying. The method may further comprise genetically modifying a lymphocyte or lymphocyte population to inducibly express IL-2 or IL- 15 or receptors for the same, wherein IL-2 or IL- 15 expression or expression of receptors for the same is under the control of an T cell activation-associated promoter (e.g. NFKB promoter, NR4A promoter, NF AT promoter). The method may further comprise genetically modifying a lymphocyte or lymphocyte population to inducibly express IL-2 or IL- 15 or receptors for the same, wherein IL-2 or IL- 15
[0018] 2
[0019] 4897-8742-6199, V 1expression or expression of or receptors for the same is under the control of a promoter in which its activity is controlled by a small molecule. The method may further comprise genetically modifying a lymphocyte or lymphocyte population to inducibly signal, through an orthogonal IL-2 receptor or orthogonal IL- 15 receptor or receptors for the same, in response to an orthogonal IL-2 or IL- 15 cytokine. The method may further comprise obtaining the lymphocyte or lymphocyte population prior to step (a).
[0020] In another embodiment, there is provided a lymphocyte or lymphocyte population prepared according to the methods described herein. In yet another embodiment, there is provided aa lymphocyte or population of lymphocytes comprising an impaired Spt-Ada-Gcn5 acetyltransferase (SAGA) complex deubiquitination module. In still yet another embodiment, there is provided a lymphocyte or population of lymphocytes exhibiting increased H2B ubiquitination and sustained expression of activation and early differentiation markers. In an even further embodiment, there is provided a lymphocyte or population of lymphocytes comprising non-functional genes or genes that express functionally impaired (i) ATNX7L3 and / or USP22 gene products, (ii) one or more other gene products in FIG. 3E, and / or (iii) one or more TADA1, SUPT20H, and / or TAF5L gene products. The lymphocyte or lymphocytes may be a T cell(s), such as a regulatory T cell(s), a yb T cell(s), a helper T cell(s), a cytotoxic T cell(s), an NK cell(s), a CAR T cell(s), a TCR-engineered T cell, a TIL or engineered TIL Also provided is a method of treating cancer comprising administering to a subject in need thereof a lymphocyte, wherein the lymphocyte is (a) a lymphocyte produced according to the method as described herein; and / or (b) a lymphocyte of lymphocyte population as described herein. A further aspect comprises a method of treating cancer comprising performing in vivo gene editing of a lymphocyte in subject in need thereof to generate non-functional genes or genes that express functionally impaired (i) ATNX7L3 and / or USP22 gene products, (ii) one or more other gene products in FIG. 3F, and / or (iii) one or more TADA1, SUPT20H, and / or TAF5L gene products.
[0021] The methods may further comprise administering a CD4+ lymphocyte to said subject. The methods may further comprise administering said CAR T cell and or said CD4+ lymphocyte more than one, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 times, or weekly, twice a month, once a month, every other month every three months, every six months, or annually. The subject may be mammal, such as a human. The method may further comprise administering to said subject a radiotherapy, a chemotherapy, a second immunotherapy, or further performing a surgery. The cancer may be recurrent, metastatic or drug resistant. The cancer may be a renal
[0022] 3
[0023] 4897-8742-6199, V 1cell cancer, melanoma, prostate cancer, bladder cancer, bone cancer, bone marrow cancer, brain cancer, breast cancer, colon cancer, esophageal cancer, gastrointestinal cancer, gum cancer, head & neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, stomach cancer, testicular cancer, oral cancer, uterine cancer, lymphoma, leukemia (CML, AML), or multiple myeloma. The subject may be administered IL-2 or IL- 15 via systemic administration or administration local or regional to a tumor or cancer site, such as wherein the lymphocyte is a TIL and / or the cancer is melanoma, and / or wherein the lymphocyte / TIL has a knock-out or disruption of one or more SAGA genes.
[0024] In an additional embodiment, there is provided a method of treating cancer in a subject comprising administering a lymphocyte or lymphocyte population comprising inhibition of SAGA gene expression, in combination with mimicking of IL-2 or IL- 15 signaling, such as orthogonal IL-2 or IL- 15 systems, expression of synthetic cytokine receptors that signal constitutively or inducibly, or expression of STAT5 or other STAT transcription factors. The inhibition of SAGA gene expression may comprise a knock-out or disruption one or more SAGA genes, or dominant-negative inhibition of SAGA gene expression.
[0025] Additionally, there is contemplated knock-out or disruption of any or multiple SAGA genes in combination with systemic or local administration of recombinant human IL-2 or IL-15. The method may be with patients currently receiving TIL therapy for, e.g., melanoma also receive infusions of recombinant human IL-2. Editing TIL to knock-out or knock-down 1 or more SAGA genes with then leverage IL-2 dosing to boost proliferation of TIL cells in patients.
[0026] The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The word “about” means plus or minus 5% of the stated number.
[0027] It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.
[0028] 4
[0029] 4897-8742-6199, V 1BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0031] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0032] FIG. 1. 143B human osteosarcoma endogenously expresses HER2. The inventors targeted lymphocytes with a HER2-guided CAR that contains a 41
[0033]
[0034] co-stimulatory domain.
[0035] FIGS. 2A-H. CRISPR-Cas12a technology allows for compact screens with high editing efficiency. FIG. 2A. Schematic of CRISPR-Cas12a screening system. Cas12a has internal RNA-processing domain that allows for multi-guide transcript processing from single array. FIG. 2B. Comparative functional knockout efficiency of Cas12a guides targeting conserve protein domains versus non-domain or non-coding regions across two pooled screens.
[0036] FIG. 2C. Result of pooled dropout screen in cancer cells against epigenetic regulators. Scatter plot compares the average log2fold change (avg. LFC) of CRISPR RNA targeting a given protein domain across two independent replicates (r = 0.96, Pearson correlation). Red dots label known drug targets. FIG. 2D. Comparison of Cas12a and Cas9 in pooled dropout screen against epigenetic regulators in cancer cells. Scatter plot compares the avg. LFC of CRISPR RNA targeting a given protein domain across two biological replicates (r = 0.93. Pearson correlation). Red dots label known drug targets. FIG. 2E (left). Knockout efficiency of two surface markers in Cas12a and guide double-positive primary human T cells exceeds 90%.
[0037] FIG. 2E (right, top). Expression of Cas12a and CAR, respectively, in guide+primary human T cells. Cas12a expression measured by fluorescent marker. FIG. 2E (right. Bottom). Guide expression in primary human T cells is enriched during expansion phase (Days 4-10) with blasticidin selection. The guide cassette contains both fluorescent marker and blasticidin resistance gene.
[0038] FIGS. 3A-E. In vivo genome-scale screen in CAR T cells meets quality control standards. FIG.3A. Schematic of screen setup. After isolation, CAR TILs harvested from 60 tumors of 30 mice are pooled in groups of 5 (Tumor 1-6). FIG. 3B. Distribution of raw guide counts in each sample, where “infusion” refers to control sample at time of CAR T infusion into mice, and “tumor” refers to pool of all TIL counts (Tumor 1-6, AKA Tl-6). FIG. 3C.
[0039] 5
[0040] 4897-8742-6199, V 1Distribution of guide log2(Fold Change) (LFC) for guides targeting genes not-expressed in T cells, when comparing pooled tumor counts to infusion control. Range of -0.60 to 0.93 LFC represents 95% of guides targeting non-expressed genes. FIG.3D. Distribution of guide LFC for guides targeting core essential genes defined by DEPMAP, when comparing pooled tumor counts to infusion control. Guide depletion in CAR TIL sample represented by negative LFC.
[0041] FIG. 3E. Positively enriched hits identified across 2 healthy donor replicates. These include PDPK1, CCNC, MED12, FLU, SOCS1. MED13, MED19, MED15, MED24, BCOR, RASAL3, PIK3CD, KIAA0922, GATA3, B3GNT2, OR2B11, JARID2, MAPK14, DMBX1, AEBP2, HS3ST6, PRIMA1, EIF4G2, L3HYPDH, PRDM6.
[0042] FIGS. 4A-C. In vivo genome-scale screen in CAR T cells identifies previously described and novel factors that enhance or regulate human CAR T in vivo persistence. FIG. 4A. Guides against factors within the SAGA Complex deubiquitination module (ATXN7L3, USP22), the Mediator Complex kinase module (MED12, CCNC), and FLU were strongly enriched in tumor-infiltrating CAR T cells. Guides against CD47, known to improve CAR T persistence, were depleted in tumor-infiltrating CAR T. FIG.4B. Log2(Fold Change) of ATXN7L3 and USP22 guides comparing CAR TIL to infusion control. Both donors used in screen shown. FIG. 4C. Guides against multiple members of the SAGA complex were enriched in the screen, both in the deubiquitination and core modules.
[0043] FIGS. 5A-F. USP / ATX KO CAR T cells have robust in vitro proliferation and persistence and altered surface phenotype. FIG. 5A. Histone H2B ubiquitination is increased in USP / ATX KO CAR T cells. FIGS.5B-D. USP / ATX KO CAR T cells proliferate for months in IL2-containing (FIGS. 5B-C) cultures but lose proliferation shortly after IL2-withdrawal (FIG. 5D). FIG. 5E. USP / ATX KO cells have increased naive / memory markers such as CD62L and CCR7, and activation as CD25. FIG. 5F. USP / ATX KO have similar osteosarcoma tumor control to WT CAR T in vitro, tested in several donors at multiple effectortarget (E: T) ratios. Shown is an example donor at 1:4 E: T, plotted by relative tumor count.
[0044] FIGS. 6A-B. ATXKO / USPKO CAR T cells have limited efficacy as sole therapy in in vivo osteosarcoma tumor control. FIG. 6A. 143B osteosarcoma tumor growth measurements for mice receiving control or ATXKO / USPKO CAR t cells. FIG. 6B. Tumor harvest at study endpoint reveals over 100-fold fewer CAR TIL in ATXKO conditions relative to control.
[0045] 6
[0046] 4897-8742-6199, V 1FIGS. 7A-D. ATXKO / USPKO CAR T lack IL-2 production, which can be rescued by CD8-specific ATXKO / USPKO. FIG. 7A. Cytokine array using supernatants from WT (control) or USP22 KO CAR T - tumor cocultures. Two cytokines commonly associated with CAR T cells are highlighted (black box = IFNy, red box = IL-2). FIG. 7B. IL-2 ELISA quantification of cocultures from WT control and USP / ATX KO CAR T cells. FIG.7C. CD4+ CAR T cells produce majority of IL-2 in WT CAR T:tumor cocultures, quantified by ELISA of 24 hr coculture supernatant. FIG. 7D. 1:1 mix of WT CD4: USP / ATX KO CD8 restores majority of IL-2 secretion.
[0047] FIG. 8. CD8-specific ATXKO can be rescued by control CD4 CAR T cells. Data show in vivo osteosarcoma tumor volume measurements in mice treated with various 1:1 CD4: CD8 mixes of WT and ATX KO CAR T cells.
[0048] FIG.9A-B. USPKO / ATXKO CAR T cells respond more robustly and at lower doses of IL-2 than control. FIG. 9A. Primary human CAR T cells were rested in cytokine-free complete media for 3 days, before supplemented with reported concentrations of IL-2. Cell number was determined 3 days after IL-2 addition, and relative cell expansion was calculated for each condition versus a cytokine-free control. Results from 1 representative donor shown from 2 tested. FIG.9B. Primary human CD4 and CD8 CAR T cells with USP22 or ATXN7L3 KO have higher downstream phosphoSTAT5 in response to various doses of IL-2. T cells were rested in RPMI with 0.1% FBS for 5 hours before stimulating with reported IL-2 dose for 20 minutes, followed by immediate fixation to capture cell state. Shown is 1 representative donor of 2 tested.
[0049] FIGS. 10A-C. ATXN7L3 KO cells endowed with cell-intrinsic IL-2 clear solid tumors and massively proliferate in vivo. FIG. 10A. Constitutive IL-2 conditions enable a robust improvement in IL-2 secretion post-stimulation, in which T cells were engineered to express both CAR and IL-2 under the same promoter. Primary human CAR T cells were cocultured with Nalm6 at a 1:1 ratio. Supernatant was collected at 24, 48, and 72 hours and IL-2 concentration was determined by ELISA. FIG. 10B. T cell counts from 1- and 2.5-weeks post-T cell engraftment in NSG mice bearing 143B human osteosarcoma solid tumors. Each group contained blood counts from a minimum of 4 individual mice. FIG. 10C. Comparisons in tumor volume at 2 weeks post-T cell engraftment. ATXN7L3 KO + constitutive IL-2 conditions are smaller than control KO + constitutive IL-2 (p = 0.002).
[0050] FIGS. 11A-D. SAGA core hits similarly affect immunophenotype. FIG. 11A.
[0051] Schematic of SAGA complex shown, where gene color refers to guide enrichment in CAR TIL
[0052] 7
[0053] 4897-8742-6199, V 1samples. Splicing and TRRAP domains not included for simplicity. SAGA core KO (TADA1, TAF5L, SUPT20H) scored in screen similarly affects CAR T surface phenotype as USP / ATX KO. Flow-based immunophenotyping was performed on day 10 post-CD3 / CD28 bead stimulation CAR T cells with the respective gene KO. One representative donor shown, tested in 2 healthy donors. Shown are markers CCR7 (FIG. 11B) and CD25 (FIG. 11C). CAR-T cells were stimulated in the presence of antigen-i- tumor cells and monensin for 6 hours, then intracellular staining for cytokine and other cytotoxic markers was performed. One representative donor shown, tested in 2 healthy donors. FIG. 11D. SAGA core KO similarly have diminished IL-2 production as USP / ATX KO (CD4+ CAR+ cells plotted in histogram).
[0054] FIGS. 12A-B. ATXN7L3 or USP22 KO increases granzyme production in both CD4 and CD8 CAR T cells. Granzyme B expression shown in CD4 (FIG. 12A) and CD8 (FIG. 12B) cells. In short, primary human CAR-T cells were stimulated in the presence of antigen-i- tumor cells and monensin for 6 hours, then intracellular staining for cytokine and other cytotoxic markers was performed. Representative donor shown from 3 individual healthy donors.
[0055] FIGS. 13A-E. Guides against PRC2 cofactors JARID2 and AEBP2 are enriched in vivo, have enhanced in vitro persistence, and favorably alter CAR T phenotype and tumor control. FIG. 13A. Guides against JARID2 and AEBP2 were enriched in CAR TIL from original in vivo screen, plotted by Log 2 (-Fold Change) (LFC). FIG. 13B. CD8+ cells were immunophenotyped by flow. JARID2 and AEBP2 KO primary human CAR T cells have enriched CD62L and CD25 expression relative to control. Results from 1 representative donor shown from 2 tested. FIG. 13C. Median fluorescence intensity (MFI) shown for both markers.
[0056] FIG. 13D. Both JARID2 and AEBP2 increase CAR T cell proliferative capacity and persistence in in vitro IL-2+ cultures. FIG. 13E. AEBP2 KO CAR T cells have improved osteosarcoma solid tumor control relative to control -treated mice.
[0057] FIG. 14. Ablation of ATXN7L3 or USP22 in primary human T cells and CART cells results in enhanced expansion. Cells were stimulated with anti-CD3 / CD28 magnetics beads on day 0, transduced with virus containing Cas12a, respective guide, and respective CARs on days 1-3, before removing anti-CD3 / CD28 beads on day 4. After bead removal, guide-i- cells were selected for 4 days with blasticidin. After which, cells were passage in IL-2-containing media without additional stim for the remainder of the assay. For each condition, results shown are pooled from 3 healthy donors.
[0058] 8
[0059] 4897-8742-6199, V 1FIG.15. Genetic knockout of ATXN7L3 or USP22 in human HER2.41BBz CART cells results in an increase in T cell activation markers and memory markers relative to control. Shown are flow cytometry proportions from day 21 of in vitro culture with 3 healthy donors, gating on live, CD8+, guide+, CAR+ cells.
[0060] FIG.16. USP22 mutants reveal that deubiquitination is central to the SAGA effect, and that USP22 is a central regulator of CAR T proliferation and senescence. (Left) Wildtype USP22 (USP22 WT) is responsible for de-ubiquitination of histone H2B. By mutating a key catalytic residue (C185S), mutant USP22 USP22 MT) is no longer able to deubiquitinate its targets. (Middle) Overexpression of mutant USP22 in CAR T cells results in enhanced proliferation, while wild-type USP22 decreases the expansion of CAR T cells. Experiments represent data from 3 healthy donors. (Right) Overexpression of mutant USP22 in CAR T cells trends (p = 0.1460) towards lowered IL-2 expression in antigen-stimulated CAR T cells. Surface markers of senescence are decreased in USP22 MT CAR T cells (5 healthy donors).
[0061] FIG. 17. CAR-T cells with stimulated with at 1:1 effector:target ratio, with target bearing their respective antigen. Independent of CAR scEV or costim, ATXKO / USPKO CAR-T have decreased IL-2 production. Shown are results from 3 healthy donors for all conditions.
[0062] FIG. 18. Bulk RNA sequencing of ATXKO / USPKO CAR-T cells reveals an alteration to IL-2 signaling, shown by both enrichment and de-enrichment of HALLMARK IL2 STAT5 signaling when comparing ATXKOVS CtrlKo transcriptomes.
[0063] MYC targets and MTORC1 signaling, other downstream signaling components of IL-2, are increased in knockout, further supporting an altered response to IL-2.
[0064] FIG.19. ATXKO / USPKO CAR-T have enhanced proliferation and sensitivity to cg-chain cytokines. Shown is proliferation data from 3 healthy donors HER2. BBz CAR T cells with respective knockout condition. Cells were passaged in complete advanced RPMI media supplemented with the following cytokine: low IL-2 = 10 HJ / mL IL-2, Low IL- 15 = 2 ng / mL, High IL- 15 = 10 ng / mL, Low IL-7 = 5 ng / mL, High IL-7 = 25 ng / mL.
[0065] FIG. 20. HER2. BBz CAR-T cells constitutively expressing IL-2 were engineered with a retroviral backbone containing HER2. BBz CAR - P2A linker - IL-2. Validation of IL-2 production after coculture with antigen-i- tumor cells, indicating constitutive IL-2 expression with construct. Representative donor of 2 experiments.
[0066] FIGS.21A-G. Constitutive IL-2 response. (FIG. 21A) Constitutive IL-2 experiments were performed in 2 healthy donors. (FIG. 2 IB) Tumor volume decreased in ATXKO +
[0067] 9
[0068] 4897-8742-6199, V 1constitutive IL-2 vs control. (FIG. 21C) T cells are substantially increased in circulating blood of mice receiving ATXKO CAR T paired with constitutive IL-2. (FIG. 2 ID) Circulating CAR T cells significantly skew towards CD8 when ATXKO CAR T is paired with constitutive IL-2. (FIGS. 21E-F) Lower expression of exhaustion and senescence markers on ATXKO CAR T + constitutive IL-2. (FIG. 21G) Toxicity in mice receiving ATXKO + constitutive IL-2.
[0069] FIGS. 22A-D. IL-2 inject + ATXko produces controlled anti-tumor immunity.
[0070] (FIG. 22A) Setup of in vivo IL-2 injection experiments, performed in 2 healthy donors. (FIG.
[0071] 22B) Circulating blood counts from a representative donor are shown, with a substantial enrichment in circulating T cells for ATXKO + IL-2. (FIG. 22C) ATXKO + IL-2 enables an enhancement in anti-tumor response relative to control. (FIG. 22D) Systemic IL-2 toxicity is reversible after discontinuing IL-2 injection.
[0072] FIGS. 23A-F. Tumor-localized induction of IL-2 expression enables safe and regulatable control of ATXKO CAR T anti-tumor response. (FIG. 23A) NSG mice were engrafted with CD 19+ 143b osteosarcoma, enabling targeting with an anti-HER2. BBz CAR T armored with anti-CD19 SNIPR that induces IL-2 expression upon binding target. (FIG. 23B) Tumor growth significantly improved with SN1PR / IL-2 circuit (representative donor of 3 experiments, n=5 mice / condition). (FIG. 23C) Mouse mass unaffected by addition of SNIPR / IL-2 circuit (representative donor of 3 experiments, n=5 mice / condition). (FIG. 23D) Tumor harvests reveal a significant increase in TIL numbers / tumor when comparing ATXKO vs C rl KO (Lognormal Welch’s T-test, n=7-8 / condition, pooled counts from 2 healthy donor experiments). (FIG. 23E) SNIPR TIL had an increased skewing of CD8+effector T cells when comparing ATXKO VS Cirko (Lognormal Welch’s T-test, n=7-8 / condition, pooled counts from 2 healthy donor experiments). (FIG. 23F) Flow surface phenotype of SNIPR TIL reveals a significantly increased expression of CD28 activation marker (Lognormal Welch’s T-test, n=4 / condition, 1 healthy donor experiment).
[0073] FIG.24. Addition of IL-2, IL-7, or IL-15 to repeat tumor cocultures enhances in vitro ATXKO HER2. BBZ CART anti-tumor immunity relative to control. Data was collected using GFP+ 143b osteosarcoma cells to track tumor cell count using the Incucyte analyzer. Shown is 1 representative of 2 healthy donors.
[0074] FIG. 25. Small molecule inhibitor of USP22 has dose-dependent response on phenotype of primary human CAR T and T cells. Shown is 1 representative of 2 healthy donors.
[0075] 10
[0076] 4897-8742-6199, V 1DETAILED DESCRIPTION
[0077] As discussed above, the curative potential of chimeric antigen receptor (CAR) T cellbased cancer immunotherapies has been widely established but remains to be fully utilized due to the limitations in CAR-T viability, persistence and expansion. Here, the inventors conducted an in vivo genome-scale CRISPR KO screen to identify regulators of human CAR T cell intratumoral persistence. Components of the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex deubiquitination module, ATXN7L3 and USP22, were identified as the two most enriched hits across two donors. Knock out of these two targets resulted in CAR T cells persisting and proliferate for months in in vitro cultures but did not exhibit improved in vivo antitumor immunity and had only limited in vivo intratumoral persistence. The inventors determined that this was due to a defect in IL-2 production, with supplementation of IL-2 restoring in vivo tumor control.
[0078] In sum, the inventors have performed an in vivo genome-scale CRISPR knockout screen of CAR T persistence and expansion, which identified ATXN7L3 and USP22 as the top two hits. These findings generate new insight into the epigenetic regulation of human CAR T cells and establish a novel role for the SAGA complex and histone ubiquitination in regulating T cell biology. These and other aspects of the disclosure are set out in detail below.
[0079] I. Definitions
[0080] Unless otherwise defined, scientific and technical terms used herein shall have the meaning that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, antibodies and related molecules, cell and tissue culture, molecular biology and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well-known and commonly used in the art.
[0081] Standard techniques are used for recombinant DNA, oligonucleotide synthesis, and cell culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques are performed according to manufacturer’s specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and
[0082] 11
[0083] 4897-8742-6199, V 1procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., B. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984); J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989); T. A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991); D. M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996); and F. M. Ausubel et al., (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present); Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988); and J. E. Coligan et al., (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates until present).
[0084] The description and definitions of variable regions and parts thereof, immunoglobulins, antibodies and fragments thereof herein may be further clarified by the discussion in Kabat Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md. (1987 and 1991); Bork et al., J Mol. Biol. 242, 309-320 (1994); Chothia and Lesk J. Mol Biol.
[0085] 196:901-917 (1987), Chothia et al., Nature 342, 877-883 (1989), and / or or Al-Lazikani et al., J Mol Biol 273, 927-948 (1997).
[0086] As used herein, “antigen-binding site” shall be taken to mean a structure formed by a protein that is capable of binding or specifically binding to an antigen, such as an antibody. The antigen-binding site need not be a series of contiguous amino acids, or even amino acids in a single polypeptide chain. For example, in a Fv comprising two different polypeptide chains from an antibody, the antigen-binding site is made up of a series of amino acids of a VL and a VH that interact with the antigen and that are generally, however not always in one or more of the CDRs in each variable region. In some embodiments, the antigen-binding site is an antigenbinding site of an antibody. In such embodiments, the antigen-binding site may comprise one or more complementarity-determining regions or “CDRs”. In some embodiments, the antigenbinding site of an antibody comprises at least part of a VH or a VL or a Fv.
[0087] 2.5F is a small, engineered peptide of ~3.5 kDa, conformationally constrained cystine knot peptide, that binds with high affinity and unique specificity to αvβ1, αvβ3, αvβ5, αvβ6 and α5β1 integrins. The cystine knot structural family, also known as knottins, consists of small polypeptides (30-50 amino acids) linked by at least three interwoven disulfide bonds, creating a rigid molecular “knot” that confers high chemical, thermal, and proteolytic stability. EETI
[0088] 12
[0089] 4897-8742-6199, V 12.5F, which is based on the Ecballium elaterium trypsin inhibitor-II, was identified via high- throughput screening of yeast-displayed knottin libraries (Kimura el al., Proteins 77(2):359- 369, 2009). See also U. S. Patent 9,913,878.
[0090] As used herein the phrase “chimeric antigen receptor (CAR)” refers to a recombinant or synthetic molecule which combines antibody-based specificity for a desired antigen with a T cell receptor-activating intracellular domain to generate a chimeric protein that exhibits cellular immune activity to the specific antigen.
[0091] As used herein the phrase “T Cell Receptor” or “TCR” refers to soluble and non-soluble forms of recombinant T-cell receptor.
[0092] As used herein, a “T-cell receptor (TCR) fusion protein” or “TTP” includes a recombinant polypeptide derived from the various polypeptides comprising the TCR that is generally capable of i) binding to a surface antigen on target cells and ii) interacting with other polypeptide components of the intact TCR complex, typically when co-located in or on the surface of a T-cell.
[0093] As used herein a “T Cell Receptor-like antibody (TCRL” or “peptide-centric CAR (PC-CAR)” refers to an antibody which binds an MHC displaying an HLA-restricted peptide antigen. Binding of TCRL to its target typically has an MHC-restricted specificity: the TCRL does not bind the MHC in the absence of the complexed peptide, and the TCRL does not bind the peptide in an absence of the MHC. TCRLs are characterized by affinity sufficient to permit specific binding to a tumor antigen even when the TCRL is provided in a soluble, rather than membrane-bound, form. TCRLs are being developed as a new therapeutic class for targeting tumor cells and mediating their specific killing. In addition, TCRLs are valuable research reagents enabling the study of human class I peptide-MHC ligand presentation and TCR-peptide-MHC interactions.
[0094] As used herein the phrase “MHC (or HLA)-restricted peptide” refers to a peptide which is potentially presented on an MHC molecule. Such peptides may be identified by laboratory procedures such as Mass-Spectrometry, reverse-immunology or by in-silico analysis. An MHC (or HLA) -presented peptide refers to a peptide which is confirmed in vitro or in vivo as being presented by an MHC molecule.
[0095] The term “cancer” as used herein is defined as a disease characterized by the rapid and uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body.
[0096] 13
[0097] 4897-8742-6199, V 1The terms “normoxia” and “hypoxia” are generally known to those of skill in the art. In general, oxygen levels in tumors range from about 0.3 to 4.2% oxygen but are mostly below 2%, whereas oxygen levels in normal tissues range from about 3.4 to 6.8% oxygen, mostly above 4%. See McKeown S.. Br. J, Radiol. 87(1035), 2014. For the purposes of this application, normoxia is defined as 3,0% or higher oxygen while hypoxia is lower than 3.0% oxygen.
[0098] A “compound” refers to any molecule including small molecules, polypeptides, and other macromolecules. In some embodiments, a compound is a small molecular weight compound with a molecular weight of less than about 2000 Daltons.
[0099] The term “naturally occurring” (or “native”) as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally occurring.
[0100] The term “operably linked” as used herein refers to positions of components so described that are in a relationship permitting them to function in their intended manner. For example, a control sequence “operably linked” to a coding sequence is connected in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
[0101] The term “protein” shall be taken to include a single polypeptide chain, i.e., a series of contiguous amino acids linked by peptide bonds or a series of polypeptide chains covalently or non-covalently linked to one another (i.e., a polypeptide complex). For example, the series of polypeptide chains can be covalently linked using a suitable chemical linker or a disulphide bond, for example. Examples of non-covalent bonds include hydrogen bonds, ionic bonds, Van der Waals forces, and hydrophobic interactions.
[0102] The term “polypeptide” or “polypeptide chain” will be understood from the foregoing paragraph to mean a series of contiguous amino acids linked by peptide bonds.
[0103] The term “polynucleotide” as referred to herein means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, or RNA-DNA hetero-duplexes. The term includes single and double stranded forms of DNA.
[0104] The term “sequence identity” means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue -by-residue basis) over the
[0105] 14
[0106] 4897-8742-6199, V 1comparison window. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms “substantial identity” as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more preferably at least 99 percent sequence identity, as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence.
[0107] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology - A Synthesis (2ndEdition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991))).
[0108] The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and may, but not always, have specific three-dimensional structural characteristics, as well as specific charge characteristics.
[0109] The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.
[0110] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as an acknowledgment, or any form of suggestion, that they constitute valid prior art or form part of the common general knowledge in any country in the world.
[0111] 15
[0112] 4897-8742-6199, V 1In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. The term “about”, when immediately preceding a number or numeral, means that the number or numeral ranges plus or minus 10%. It should be understood that the terms “a" and “an” as used herein refer to “one or more” of the enumerated components unless otherwise indicated. The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. The term “and / or” should be understood to mean either one, or both of the alternatives. As used herein, the terms “include” and “comprise” are used synonymously.
[0113] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0114] II. Lymphocytes
[0115] In accordance with the present disclosure, there are provided lymphocytes and lymphocyte populations that have been modified to reduce or eliminate expression of ATXN7L3 and USP22 and methods of making the same.
[0116] A lymphocyte is a type of white blood cell (leukocyte) in the immune system of most vertebrates. Lymphocytes include T cells (for cell-mediated, cytotoxic adaptive immunity), B cells (for humoral, antibody-driven adaptive immunity), and Innate lymphoid cells (ILCs) ("innate T cell-like" cells involved in mucosal immunity and homeostasis), of which natural killer cells are an important subtype (which functions in cell-mediated, cytotoxic innate immunity). They are the main type of cell found in lymph, which prompted the name "lymphocyte” (with cyte meaning cell). Lymphocytes make up between 18% and 42% of circulating white blood cells. The three major types of lymphocytes are T cells, B cells and natural killer (NK) cells. Lymphocytes can be identified by their large nucleus.
[0117] T cells (thymus cells) and B cells (bone marrow- or bursa-derived cells) arc the major cellular components of the adaptive immune response. T cells are involved in cell-mediated immunity, whereas B cells are primarily responsible for humoral immunity (relating to antibodies). The function of T cells and B cells is to recognize specific "non-self" antigens, during a process known as antigen presentation. Once they have identified an invader, the cells generate specific responses that are tailored maximally to eliminate specific pathogens or pathogen-infected cells. B cells respond to pathogens by producing large quantities
[0118] 16
[0119] 4897-8742-6199, V 1of antibodies which then neutralize foreign objects like bacteria and viruses. In response to pathogens some T cells, called T helper cells, produce cytokines that direct the immune response, while other T cells, called cytotoxic T cells, produce toxic granules that contain powerful enzymes which induce the death of pathogen-infected cells. Following activation, B cells and T cells leave a lasting legacy of the antigens they have encountered, in the form of memory cells. Throughout the lifetime of an animal, these memory cells will "remember" each specific pathogen encountered and are able to mount a strong and rapid response if the same pathogen is detected again; this is known as acquired immunity.
[0120] NK cells are a part of the innate immune system and play a major role in defending the host from tumors and virally infected cells. NK cells modulate the functions of other cells, including macrophages and T cells, and distinguish infected cells and tumors from normal and uninfected cells by recognizing changes of a surface molecule called MHC (major histocompatibility complex) class I. NK cells are activated in response to a family of cytokines called interferons. Activated NK cells release cytotoxic (cell-killing) granules which then destroy the altered cells. They are named “natural killer cells" because they do not require prior activation in order to kill cells which are missing MHC class I.
[0121] A. Antibody Producing Cells / B Cells
[0122] B cells, also known as B lymphocytes, are a type of while blood cell of the lymphocyte subtype. They function in the humoral immunity component of the adaptive immune system. B cells produce antibody molecules which may be either secreted or inserted into the plasma membrane where they serve as a part of B -cell receptors. When a naive or memory B cell is activated by an antigen, it proliferates and differentiates into an antibody-secreting effector cell, known as a plasmablast or plasma cell. Additionally. B cells present antigens (they are also classified as professional antigen-presenting cells (APCs)) and secrete cytokines. In mammals, B cells mature in the bone marrow, which is at the core of most bones.
[0123] B cells, unlike the other two classes of lymphocytes, T cells and natural killer cells, express B cell receptors (BCRs) on their cell membrane. BCRs allow the B cell to bind to a foreign antigen, against which it will initiate an antibody response. B cell receptors are extremely specific, with all BCRs on a B cell recognizing the same epitope.
[0124] B cells develop from hematopoietic stem cells (HSCs) that originate from bone marrow. HSCs first differentiate into multipotent progenitor (MI’P) cells, then common lymphoid progenitor (CLP) cells. From here, their development into B cells occurs in several
[0125] 17
[0126] 4897-8742-6199, V 1stages (shown in image to the right), each marked by various gene expression patterns and immunoglobulin H chain and L chain gene loci arrangements, the latter due to B cells undergoing V(D)J recombination as they develop.
[0127] B cells undergo two types of selection while developing in the bone marrow to ensure proper development, both involving B cell receptors (BCR) on the surface of the cell. Positive selection occurs through antigen-independent signaling involving both the pre-BCR and the BCR. If these receptors do not bind to their ligand, B cells do not receive the proper signals and cease to develop. Negative selection occurs through the binding of self-antigen with the BCR; if the BCR can bind strongly to self-antigen, then the B cell undergoes one of four fates: clonal deletion, receptor editing, anergy. or ignorance (B cell ignores signal and continues development). This negative selection process leads to a state of central tolerance, in which the mature B cells do not bind self-antigens present in the bone marrow.
[0128] To complete development, immature B cells migrate from the bone marrow into the spleen as transitional B cells, passing through two transitional stages: T1 and T2. Throughout their migration to the spleen and after spleen entry, they are considered T1 B cells. Within the spleen, T1 B cells transition to T2 B cells. T2 B cells differentiate into either follicular (FO) B cells or marginal zone (MZ) B cells depending on signals received through the BCR and other receptors. Once differentiated, they are now considered mature B cells, or naive B cells.
[0129] B cell activation occurs in the secondary lymphoid organs (SLOs), such as the spleen and lymph nodes. After B cells mature in the bone marrow, they migrate through the blood to SLOs, which receive a constant supply of antigen through circulating lymph. At the SLO, B cell activation begins when the B cell binds to an antigen via its BCR.3Although the events taking place immediately after activation have yet to be completely determined, it is believed that B cells are activated in accordance with the kinetic segregation model, initially determined in T lymphocytes. This model denotes that before antigen stimulation, receptors diffuse through the membrane coming into contact with Lek and CD45 in equal frequency, rendering a net equilibrium of phosphorylation and non -phosphorylation. It is only when the cell conies in contact with an antigen presenting cell that the larger CD45 is displaced due to the close distance between the two membranes. This allows for net phosphorylation of the BCR and the initiation of the signal transduction pathway. Of the three B cell subsets, FO B cells preferentially undergo T cell-dependent activation while MZ B cells and Bl B cells preferentially undergo T cell-independent activation.
[0130] 18
[0131] 4897-8742-6199, V 1B cell activation is enhanced through the activity of CD21, a surface receptor in complex with surface proteins CD 19 and CD81 (all three are collectively known as the B cell coreceptor complex). When a BCR binds an antigen tagged with a fragment of the C3 complement protein. CD21 binds the C3 fragment, co-ligates with the bound BCR, and signals are transduced through CD19 and CD81 to lower the activation threshold of the cell.
[0132] B. T Cells
[0133] T cells play a central role in the adaptive immune response. T cells can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface. T cells are born from hematopoietic stem cells, found in the bone marrow. Developing T cells then migrate to the thymus gland to develop (or mature). T cells derive their name from the thymus. After migration to the thymus, the precursor cells mature into several distinct types of T cells. T cell differentiation also continues after they have left the thymus. Groups of specific, differentiated T cell subtypes have a variety of important functions in controlling and shaping the immune response.
[0134] One of these functions is immune-mediated cell death, and it is carried out by two major subtypes: CD8+ "killer" (cytotoxic) and CD4+ "helper" T cells. (These are named for the presence of the cell surface proteins CD8 or CD4.) CD8+ T cells, also known as "killer T cells", are cytotoxic - this means that they are able to directly kill virus-infected cells, as well as cancer cells. CD8+ T cells are also able to use small signaling proteins, known as cytokines, to recruit other types of cells when mounting an immune response. A different population of T cells, the CD4+ T cells, function as "helper cells". Unlike CD8+ killer T cells, the CD4+ helper T (TH) cells function by further activating memory B cells and cytotoxic T cells, which leads to a larger immune response. The specific adaptive immune response regulated by the TH cell depends on its subtype (such as T-helperl, T-helper2, T-helperl7, regulatory T-cell), which is distinguished by the types of cytokines they secrete.
[0135] Regulatory T cells arc yet another distinct population of T cells that provide the critical mechanism of tolerance, whereby immune cells are able to distinguish invading cells from "self". This prevents immune cells from inappropriately reacting against one's own cells, known as an "autoimmune" response. For this reason, these regulatory T cells have also been called "suppressor" T cells. These same regulatory T cells can also be co-opted by cancer cells to prevent the recognition of, and an immune response against, tumor cells.
[0136] 19
[0137] 4897-8742-6199, V 1All T cells originate from c-kit+Scal+hematopoietic stem cells (HSC) which reside in the bone marrow. In some cases, the origin might be the fetal liver during embryonic development. The HSC then differentiate into multipotent progenitors (MPP) which retain the potential to become both myeloid and lymphoid cells. The process of differentiation then proceeds to a common lymphoid progenitor (CLP), which can only differentiate into T, B or NK cells. These CLP cells then migrate via the blood to the thymus, where they engraft; henceforth they are known as thymocytes, the immature stage of a T cell.
[0138] The earliest cells which arrived in the thymus are commonly termed double-negative, as they express neither the CD4 nor CD8 co-receptor. The newly arrived CLP cells are CD4“CD8“CD44+CD25“ckit+cells, and are termed early thymic progenitor (ETP) cells. These cells will then undergo a round of division and downregulate c-kit and are termed doublenegative one (DN1) cells. To become T cells, the thymocytes must undergo multiple DN stages as well as positive selection and negative selection. Double negative thymocytes can be identified by the surface expression of CD2, CD5 and CD7. Still during the double negative stages, CD34 expression stops and CD1 is expressed. Expression of both CD4 and CD8 makes them double positive and matures into either CD4+ or CD8+ cells.
[0139] A critical step in T cell maturation is making a functional T cell receptor (TCR). Each mature T cell will ultimately contain a unique TCR that reacts to a random pattern, allowing the immune system to recognize many different types of pathogens. This process is essential in developing immunity to threats that the immune system has not encountered before, since due to random variation there will always be at least one TCR to match any new pathogen.
[0140] A thymocyte can only become an active T cell when it survives the process of developing a functional TCR. The TCR consists of two major components, the alpha and beta chains. These both contain random elements designed to produce a wide variety of different TCRs, but due to this huge variety they must be tested to make sure they work at all. First, the thymocytes attempt to create a functional beta chain, testing it against a 'mock' alpha chain. Then they attempt to create a functional alpha chain. Once a working TCR has been produced, the cells then must test if their TCR will identify threats correctly, and to do this it is required to recognize the body’s major histocompatibility complex (MHC) in a process known as positive selection. The thymocyte must also ensure that it does not react adversely to "self" antigens, called negative selection. If both positive and negative selection are successful, the TCR becomes fully operational and the thymocyte becomes a T cell.
[0141] 20
[0142] 4897-8742-6199, V 1C. Chimeric Antigen Receptors and CAR T Cells
[0143] Chimeric antigen receptors (CARs) - also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors - are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor. CAR T cell therapy uses T cells engineered with CARs to treat cancer. The premise of CAR T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR T cells into patients to attack their tumors.
[0144] CAR T cells can be derived either from T cells in a patient's own blood (autologously) or from the T cells of another, healthy, donor (allogeneically). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, using a vector derived from an engineered lentivirus such as HIV (see Lentiviral vector in gene therapy). The CAR programs the recipient’s T cells to target an antigen that is present on the surface of tumors. For safety, CAR T cells are engineered to be specific to an antigen that is expressed on a tumor but is not expressed on healthy cells.
[0145] After CAR T cells are infused into a patient, they act as a "living drug" against cancer cells. When they come in contact with their targeted antigen on a cell's surface, CAR T cells bind to it and become activated, then proceed to proliferate and become cytotoxic. CAR T cells destroy cells through several mechanisms, including extensive stimulated cell proliferation, increasing the degree to which they are toxic to other living cells (cytotoxicity), and by causing the increased secretion of factors that can affect other cells such as cytokines, interleukins and growth factors. The surface of CAR T cells can bear either of two types of coreceptors, CD4 and CD8. These two cell types, called CD4+ and CD8+, respectively, have different and interacting cytotoxic effects, and it appears that therapies employing a 1 -to- 1 ratio of the cell types provide synergistic antitumor effects.
[0146] Thus, in an embodiment of the disclosure, there is provided a T-cell receptor fusion protein (TFP) comprising:
[0147] a) a T-cell receptor (TCR) subunit comprising:
[0148] (i) at least a portion of a TCR extracellular domain, and
[0149] (ii) a TCR intracellular domain comprising a stimulatory domain from an intracellular signaling domain; and
[0150] b) a binding agent of the disclosure,
[0151] 21
[0152] 4897-8742-6199, V 1wherein the TCR subunit and the binding agent are operatively linked, and wherein the TFP incorporates into a TCR when expressed in a T-cell.
[0153] As used herein, the term “at least a portion of a TCR extracellular domain” refers to α and β chains of the TCR comprising variable and constant regions or domains. The term "domain" or "region" can be used interchangeably herein. The variable domain consists of a concatenation of variable region and joining region. The term " TCR alpha variable domain" therefore refers to the concatenation of TRAV and TRAJ regions, and the term TCR alpha constant domain refers to the extracellular TRAC region, or to a C-terminal truncated TRAC sequence. Likewise, the term " TCR beta variable domain" refers to the concatenation of TRBV and TRBD / TRBJ regions, and the term TCR beta constant domain refers to the extracellular TRBV region or to a C-terminal truncated TRBC sequence. The unique sequences defined by the IMGT nomenclature are widely known and accessible to those working in the TCR field. For example, they can be found in the IMGT public database. The " T cell Receptor Factsbook", (2001) LeFranc and LeFranc, Academic Press, ISBN 0-12-441352-8 also discloses sequences defined by the IMGT nomenclature, but because of its publication date and consequent timelag, the information therein sometimes needs to be confirmed by reference to the IMGT database. As used herein, the term “wherein the TCR incorporates into a TCR when expressed in a T-cell” refers to the process of a TFP of the invention being expressed and fused to a T-cell receptor of a T-cell.
[0154] Chimeric antigen receptors (CARs) are fusion proteins comprising antigen recognition moieties and T cell-activation domains. Exemplary CARs are provided by U. S. Patent.
[0155] 8,399,645 and U. S. Patent 7,638,325. Other exemplary recombinant receptors, including CARs, recombinant T-cell receptors (TCRs), TCR fusion proteins (TFPs), as well as methods for engineering and introducing the receptors into cells, include those described in Int'l Pat. Appl. Nos. WO2017 / 096329, WO2000 / 14257, WO2013 / 126726, WO2012 / 129514, WO2014031687, WO2013 / 166321, and WO2013 / 071154, WO2013 / 123061, and WO / 2014055668; U. S. Pat. App. Nos. US2002131960, US2013287748, and US20130149337; U. S. Pat. Nos. 6,451,995, 7,446,190, 7,638,325, 8,252,592, 8,339,645, 8,398,282, 7,446,179, 6,410,319, 7,070,995, 7,265,209, 7,354,762, 7,446,191, 8,324,353, and 8,479,118; European Pat. App. No. EP2537416; and Sadelain et al. Cancer Discov. April 3(4): 388-398 (2013); Davila etal. PLoS ONE 8(4): e61338 (2013); Turtle etal. Curr. Opin. Immunol. October 24(5): 633-39 (2012); and Wu et al. Cancer, March 18(2): 160-75 (2012). In an embodiment, the binding agent is a TFP as described in U. S. Pat. No. 15 / 419,398.
[0156] 22
[0157] 4897-8742-6199, V 1In certain embodiments, the present disclosure provides T cells, such as CD4+ T cells, CD8+ T cells or Tregs. engineered to contain a CAR vector and to express a CAR. Certain embodiments of the present disclosure concern obtaining a starting population of T cell, modifying the T cells to express a CAR specific for the inert cell surface molecule expressed by the stem cell-derived cells, and administering the CAR T cells to a subject to ablate the stem cell-derived cells.
[0158] In some embodiments, the starting population of T cells, such as CD4+ T cells, CD8+ T cells or Tregs, are derived from blood, cord blood, bone marrow, lymph, or lymphoid organs, such as the thymus. In some aspects, the cells are human cells. The cells typically are primary cells, such as those isolated directly from a subject and / or isolated from a subject and frozen. With reference to the subject to be treated, the cells may be allogeneic and / or autologous. In some embodiments, the methods include isolating cells from the subject, preparing, processing, culturing, and / or engineering them, as described herein, and re-introducing them into the same patient, before or after cryopreservation.
[0159] In some embodiments, one or more of the T cell populations is enriched for or depleted of cells that are positive for a specific marker, such as surface markers, or that are negative for a specific marker. In some cases, such markers are those that are absent or expressed at relatively low levels on certain populations of T cells (e.g., regulatory T cells) but are present or expressed at relatively higher levels on certain other populations of T cells (e.g., regulatory T cells).
[0160] In some embodiments, T cells, such as regulatory T cells, are separated from a peripheral blood mononuclear cell (PBMC) sample by negative selection of markers expressed on non-T cells, such as B cells, monocytes, or other white blood cells, such as CD14. In some aspects, CD4+CD25+CD127- Tregs or CD4+CD25-CD127+ T effector (Teff) cells are purified from human peripheral blood.
[0161] In some embodiments, the T cells are autologous T cells. In this method, tumor samples are obtained from patients and a single cell suspension is obtained. The single cell suspension can be obtained in any suitable manner, e.g., mechanically (disaggregating the tumor using, e.g., a gentleMACS™ Dissociator, Miltenyi Biotec, Auburn, Calif.) or enzymatically (e.g., collagenase or DNase). Single-cell suspensions of tumor enzymatic digests are cultured in interleukin-2 (IL-2). The cells are cultured until confluence (e.g., about 2×106lymphocytes), e.g., from about 5 to about 21 days, preferably from about 10 to about 14 days. For example,
[0162] 23
[0163] 4897-8742-6199, V 1the cells may be cultured from 5 days, 5.5 days, or 5.8 days to 21 days, 21.5 days, or 21.8 days, such as from 10 days, 10.5 days, or 10.8 days to 14 days, 14.5 days, or 14.8 days.
[0164] The cultured T cells can be pooled and rapidly expanded. Rapid expansion provides an increase in the number of antigen-specific T-cells of at least about 50-fold (e.g., 50-, 60-, 70-, 80-, 90-, or 100-fold, or greater) over a period of about 10 to about 14 days. More specifically, rapid expansion provides an increase of at least about 200-fold (e.g., 200-, 300-, 400-, 500-, 600-, 700-, 800-, 900-, or greater) over a period of about 10 to about 14 days. Expansion can be accomplished by any of a number of methods as are known in the art. For example, T cells can be rapidly expanded using non-specific T-cell receptor stimulation in the presence of feeder lymphocytes and either interleukin-2 (IL-2) or interleukin- 15 (IL-15). The non-specific T-cell receptor (TCR) stimulus can include around 30 ng / ml of OKT3, a mouse monoclonal anti-CD3 antibody (available from Ortho-McNeil®, Raritan, N. J.). Alternatively, T cells can be rapidly expanded by stimulation of peripheral blood mononuclear cells (PBMC) in vitro with one or more antigens (including antigenic portions thereof, such as epitope(s), or a cell) of the cancer, which can be optionally expressed from a vector, such as a human leukocyte antigen A2 (HLA-A2) binding peptide, in the presence of a T-cell growth factor, such as 300 lU / ml IL-2. In vitro-induced T-cells are rapidly expanded by re-stimulation with the same antigen(s) of the cancer pulsed onto HLA-A2-expressing antigen-presenting cells. Alternatively, the T-cells can be restimulated with irradiated, autologous lymphocytes or with irradiated HLA-A2+allogeneic lymphocytes and IL-2, for example.
[0165] The autologous T-cells can be modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells. Suitable T-cell growth factors include, for example, interleukin (IL)-2, IL-7, IL- 15, and IL- 12. Suitable methods of modification are known in the art. See, for instance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rded., Cold Spring Harbor Press, Cold Spring Harbor, N. Y. 2001; and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994. In particular aspects, modified autologous T-cells express the T-cell growth factor at high levels. T-cell growth factor coding sequences, such as that of IL-12, are readily available in the art, as are promoters, the operable linkage of which to a T-cell growth factor coding sequence promotes high-level expression.
[0166] One of skill in the art would be well-equipped to construct a vector through standard recombinant techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996, both incorporated herein by reference) for the expression of the antigen receptors of the present
[0167] 24
[0168] 4897-8742-6199, V 1disclosure. Vectors include but are not limited to, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs), such as retroviral vectors (e.g. derived from Moloney murine leukemia virus vectors (MoMLV), MSCV, SFFV, MPSV, SNV etc.), lentiviral vectors (e.g. derived from HIV-1, HIV-2, SIV, BIV, FIV etc.), adenoviral (Ad) vectors including replication competent, replication deficient and gutless forms thereof, adeno-associated viral (AAV) vectors, simian virus 40 (SV-40) vectors, bovine papilloma virus vectors, Epstein-Barr virus vectors, herpes virus vectors, vaccinia virus vectors, Harvey murine sarcoma virus vectors, murine mammary tumor vims vectors, Rous sarcoma virus vectors, parvovirus vectors, polio virus vectors, vesicular stomatitis virus vectors, maraba vims vectors and group B adenovirus enadenotucirev vectors.
[0169] In some embodiments, the CAR contains an extracellular antigen-recognition domain that specifically binds to an antigen. In some embodiments, the antigen is a protein expressed on the surface of cells. In some embodiments, the CAR is a TCR-like CAR and the antigen is a processed peptide antigen, such as a peptide antigen of an intracellular protein, which, like a TCR, is recognized on the cell surface in the context of a major histocompatibility complex (MHC) molecule.
[0170] Exemplary antigen receptors, including CARs and recombinant TCRs, as well as methods for engineering and introducing the receptors into cells, include those described, for example, in international patent application publication numbers W0200014257, WO2013126726, WO2012 / 129514, WO2014031687, WO2013 / 166321, W02013 / 071154, WO2013 / 123061, WO2023019144A1, U. S. Patent Publication Nos. US 2002131960, US2013287748, US20130149337, U. S. Patent Nos.: 6,451,995, 7,446,190, 8,252,592, 8,339,645, 8,398,282, 7,446,179, 6,410,319, 7,070,995, 7,265,209, 7,354,762, 7,446,191, 8,324,353, and 8,479,118, and European patent application number EP2537416, and / or those described by Sadelain et al., Cancer Discov. 2013 April; 3(4): 388-398; Davila et al. (2013) PLoS ONE 8(4): e61338; Turtle et al., Curr. Opin. Immunol., 2012 October; 24(5): 633-39; Wu et al., Cancer, 2012 March 18(2): 160-75. In some aspects, the genetically engineered antigen receptors include a CAR as described in U. S. Patent No.: 7,446,190, and those described in International Patent Application Publication No.: WO / 2014055668 Al.
[0171] In some embodiments, the CAR comprises (a) an intracellular signaling domain, (b) a transmembrane domain, and (c) an extracellular domain comprising an antigen binding region.
[0172] In some embodiments, the CARs include activating or stimulatory CARs, costimulatory CARs (see WO2014 / 055668), and / or inhibitory CARs (iCARs, see Fedorov et al., Sci. Transl.
[0173] 25
[0174] 4897-8742-6199, V 1Med. 2013 5(215):215). The CARs generally include an extracellular antigen (or ligand) binding domain linked to one or more intracellular signaling components, in some aspects via linkers and / or transmembrane domain(s). Such molecules typically mimic or approximate a signal through a natural antigen receptor, a signal through such a receptor in combination with a costimulatory receptor, and / or a signal through a costimulatory receptor alone.
[0175] Certain embodiments of the present disclosure concern the use of nucleic acids, including nucleic acids encoding an antigen-specific CAR polypeptide, including a CAR that has been humanized to reduce immunogenicity (hCAR), comprising an intracellular signaling domain, a transmembrane domain, and an extracellular domain comprising one or more signaling motifs. In certain embodiments, the CAR may recognize an epitope comprising the shared space between one or more antigens. In certain embodiments, the binding region can comprise complementary determining regions of a monoclonal antibody, variable regions of a monoclonal antibody, and / or antigen binding fragments thereof. In another embodiment, that specificity is derived from a peptide (e.g., cytokine) that binds to a receptor.
[0176] It is contemplated that the human CAR nucleic acids may be human genes used to enhance cellular immunotherapy for human patients. In a specific embodiment, the invention includes a full-length CAR cDNA or coding region. The antigen binding regions or domain can comprise a fragment of the VH and VL chains of a single-chain variable fragment (scFv) derived from a particular human monoclonal antibody, such as those described in U. S. Patent 7,109,304, incorporated herein by reference. The fragment can also be any number of different antigen binding domains of a human antigen-specific antibody. In a more specific embodiment, the fragment is an antigen-specific scFv encoded by a sequence that is optimized for human codon usage for expression in human cells.
[0177] The arrangement could be multimeric, such as a diabody or multimers. The multimers are most likely formed by cross pairing of the variable portion of the light and heavy chains into a diabody. The hinge portion of the construct can have multiple alternatives from being totally deleted, to having the first cysteine maintained, to a proline rather than a serine substitution, to being truncated up to the first cysteine. The Fc portion can be deleted. Any protein that is stable and / or dimerizes can serve this purpose. One could use just one of the Fc domains, e.g., either the CH2 or CH3 domain from human immunoglobulin. One could also use the hinge, CH2 and CH3 region of a human immunoglobulin that has been modified to improve dimerization. One could also use just the hinge portion of an immunoglobulin. One could also use portions of CD8alpha.
[0178] 26
[0179] 4897-8742-6199, V 1In some embodiments, the CAR nucleic acid comprises a sequence encoding other costimulatory receptors, such as a transmembrane domain and a modified CD28 intracellular signaling domain. Other costimulatory receptors include, but are not limited to one or more of CD28, CD27, OX-40 (CD134), DAP10, and 4-1BB (CD137). In addition to a primary signal initiated by CD3, an additional signal provided by a human costimulatory receptor inserted in a human CAR is important for full activation of NK cells and could help improve in vivo persistence and expansion and the therapeutic success of adoptive immunotherapy.
[0180] In some embodiments, CAR is constructed with a specificity for a particular antigen (or marker or ligand), such as an antigen expressed in a particular cell type to be targeted by adoptive therapy, e.g., a cancer marker, and / or an antigen intended to induce a dampening response, such as an antigen expressed on a normal or non-diseased cell type. Thus, the CAR typically includes in its extracellular portion one or more antigen binding molecules, such as one or more antigen-binding fragment, domain, or portion, or one or more antibody variable domains, and / or antibody molecules. In some embodiments, the CAR includes an antigenbinding portion or portions of an antibody molecule, such as a single-chain antibody fragment (scFv) derived from the variable heavy (VH) and variable light (VL) chains of a monoclonal antibody (mAb).
[0181] In certain embodiments of the chimeric antigen receptor, the antigen- specific portion of the receptor (which may be referred to as an extracellular domain comprising an antigen binding region) comprises a cell surface protein, particularly an inert cell surface protein. Antigens include carbohydrate antigens recognized by pattern-recognition receptors, such as Dectin- 1.
[0182] The sequence of the open reading frame encoding the chimeric receptor can be obtained from a genomic DNA source, a cDNA source, or can be synthesized (e.g., via PCR), or combinations thereof. Depending upon the size of the genomic DNA and the number of introns, it may be desirable to use cDNA or a combination thereof as it is found that introns stabilize the mRNA. Also, it may be further advantageous to use endogenous or exogenous non-coding regions to stabilize the mRNA.
[0183] It is contemplated that the chimeric construct can be introduced into immune cells as naked DNA or in a suitable vector. Methods of stably transfecting cells by electroporation using naked DNA are known in the art. See, e.g., U. S. Pat. No. 6,410,319. Naked DNA generally refers to the DNA encoding a chimeric receptor contained in a plasmid expression vector in proper orientation for expression.
[0184] 27
[0185] 4897-8742-6199, V 1Alternatively, a viral vector (e.g., a retroviral vector, adenoviral vector, adeno-associated viral vector, or lentiviral vector) can be used to introduce the chimeric construct into immune cells. Suitable vectors for use in accordance with the method of the present disclosure are non-replicating in the immune cells. A large number of vectors are known that are based on viruses, where the copy number of the virus maintained in the cell is low enough to maintain the viability of the cell, such as, for example, vectors based on HIV, SV40, EBV, HSV, or BPV.
[0186] In some aspects, the antigen-specific binding, or recognition component is linked to one or more transmembrane and intracellular signaling domains. In some embodiments, the CAR includes a transmembrane domain fused to the extracellular domain of the CAR. In one embodiment, the transmembrane domain that naturally is associated with one of the domains in the CAR is used. In some instances, the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
[0187] The transmembrane domain in some embodiments is derived either from a natural or from a synthetic source. Where the source is natural, the domain in some aspects is derived from any membrane-bound or transmembrane protein. Transmembrane regions include those derived from (i.e. comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T- cell receptor, CD28, CD3 zeta, CD3 epsilon, CD3 gamma, CD3 delta, CD45, CD4, CD5, CD8, CD9, CD 16, CD22, CD33, CD37, CD64, CD80, CD86, CD 134, CD137, CD154, ICOS / CD278, GITR / CD357, NKG2D, and DAP molecules. Alternatively, the transmembrane domain in some embodiments is synthetic. In some aspects, the synthetic transmembrane domain comprises predominantly hydrophobic residues such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain.
[0188] In certain embodiments, the platform technologies disclosed herein to genetically modify immune cells, such as NK cells, comprise (i) non-viral gene transfer using an electroporation device (e.g., a nucleofector), (ii) CARs that signal through endodomains (e.g., CD28 / CD3-(^, CD137 / CD3-, or other combinations), (iii) CARs with variable lengths of extracellular domains connecting the antigen-recognition domain to the cell surface, and, in some cases, (iv) artificial antigen presenting cells (aAPC) derived from K562 to be able to robustly and numerically expand CAR+immune cells (Singh et al., 2008: Singh et al, 2011).
[0189] 28
[0190] 4897-8742-6199, V 1Among the target proteins of antigens targeted by the present CARs are those expressed in the context of a disease, condition, or cell type to be targeted via the CAR. Among the diseases and conditions are proliferative, neoplastic, and malignant diseases and disorders, including cancers and tumors, including hematologic cancers, cancers of the immune system, such as lymphomas, leukemias, and / or myelomas, such as B, T, and myeloid leukemias, lymphomas, and multiple myelomas. In some embodiments, the antigen is selectively expressed or overexpressed on cells of the disease or condition, e.g., the tumor or pathogenic cells, as compared to normal or non-targeted cells or tissues. In other embodiments, the antigen is expressed on normal cells and / or is expressed on the engineered cells. Any suitable antigen may find use in the present methods. Exemplary antigens include, but are not limited to, antigenic molecules from infectious agents, auto- / self-antigens, tumor-Zcancer-associated antigens, and tumor neoantigens.
[0191] The terms “tumor-associated antigen,” “tumor antigen” and “cancer cell antigen” are used interchangeably herein. In each case, the terns refer to proteins, glycoproteins or carbohydrates that are specifically or preferentially expressed by cancer cells.
[0192] Exemplary embodiments of antigens include, but are not limited to, CD 19, CD20, carcinoembryonic antigen, alphafetoprotein, CA-125, MUC-1, CD56, EGFR, EGFRt, c-Met, AKT, Her2, Her3, epithelial tumor antigen, melanoma-associated antigen, mutated p53, mutated ras, and so forth. In particular aspects, the antigens include NY-ESO, EGFRvIII, Muc-1, Her2, CA-125, WT-1, Mage-A3, Mage-A4, Mage-AlO, TRAIL / DR4, and CEA. In particular aspects, the antigens for the two or more antigen receptors include, but are not limited to, CD19, EBNA, WT1, CD123, NY-ESO, EGFRvIII, MUC1, HER2, CA-125, WT1, Mage-A3, Mage-A4, Mage- A 10, TRAIL / DR4, and / or CEA. The sequences for these antigens are known in the art, for example, CD19 (Accession No. NG_007275.1), EBNA (Accession No. NG_002392.2), WT1 (Accession No. NG_009272.1), CD123 (Accession No. NC_000023.11), NY-ESO (Accession No. NC_000023.11), EGFRvIII (Accession No. NG_007726.3), MUC1 (Accession No. NG_029383.1), HER2 (Accession No. NG_007503.1), CA-125 (Accession No. NG_055257.1), WT1 (Accession No. NG_009272.1), Mage- A3 (Accession No. NG_013244.1), Mage-A4 (Accession No. NG_013245.1), Mage-AlO (Accession No. NC_000023.11), TRAIL / DR4 (Accession No. NC_000003.12), and / or CEA (Accession No. NC_000019.10).
[0193] Other tumor associated antigens include Plu-1, HASH-1, Hash-2, Cripto and Criptin. Additionally, a tumor antigen may be a self-peptide hormone, such as whole length
[0194] 29
[0195] 4897-8742-6199, V 1gonadotrophin hormone releasing hormone (GnRH), a short 10 amino acid long peptide, useful in the treatment of many cancers.
[0196] Tumor antigens include tumor antigens derived from cancers that are characterized by tumor-associated antigen expression, such as HER-2 / neu expression. Tumor-associated antigens of interest include lineage-specific tumor antigens such as the melanocyte-melanoma lineage antigens MART-l / Melan-A, gplOO, gp75, mda-7, tyrosinase and tyrosinase-related protein. Illustrative tumor-associated antigens include, but are not limited to, tumor antigens derived from or comprising any one or more of, p53, Ras, c-Myc, cytoplasmic serine / threonine kinases (e.g., A-Raf, B-Raf, and C-Raf, cyclin-dependent kinases), MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MART-1, BAGE, DAM-6, -10, GAGE-1, -2, -8, GAGE-3, -4, -5, -6, -7B, NA88-A, MART-1, MC1R, GplOO, PSA, PSM, Tyrosinase, TRP-1, TRP-2, ART-4, CAMEL, CEA, Cyp-B, hTERT, hTRT, iCE, MUC1, MUC2, Phosphoinositide 3-kinases (PI3Ks), TRK receptors, FRAME, Pl 5, RU1, RU2, SART-1, SART-3, Wilms' tumor antigen (WT1), AFP, -catcnin / m, Caspasc-8 / m, CEA, CDK-4 / m, ELF2M, GnT-V, G250, HSP70-2M, HST-2, KIAA0205, MUM-1, MUM-2, MUM-3, Myosin / m, RAGE, SART-2, TRP-2 / INT2, 707-AP, Annexin II, CDC27 / m, TPI / mbcr-abl, BCR-ABL, interferon regulatory factor 4 (IRF4), ETV6 / AML, LDLR / FUT, Pml / RAR, Tumor-associated calcium signal transducer 1 (TACSTD1) TACSTD2, receptor tyrosine kinases (e.g., Epidermal Growth Factor receptor (EGFR) (in particular, EGFRvIII), platelet derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR)), cytoplasmic tyrosine kinases (e.g., src-family, syk-ZAP70 family), integrin-linked kinase (ILK), signal transducers and activators of transcription STAT3, STAT5, and STAT6, hypoxia inducible factors (e.g., HIF-1 and HIF-2), Nuclear Factor-Kappa B (NF-B), Notch receptors (e.g., Notchl-4), c-Met, mammalian targets of rapamycin (mTOR), WNT, extracellular signal-regulated kinases (ERKs), and their regulatory subunits, PMSA, PR-3, MDM2, Mesothelin, renal cell carcinoma-5T4, SM22-alpha, carbonic anhydrases I (CAI) and IX (CAIX) (also known as G250), STEAD, TEL / AML1, GD2, proteinase3, hTERT, sarcoma translocation breakpoints, EphA2, ML-IAP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NAU, PAX3, ALK, androgen receptor, cyclin Bl, polysialic acid, MYCN, RhoC, GD3, fucosyl GM1, mesothelian, PSCA, sLe, PLAC1, GM3, BORIS, Tn, GLoboH, NY-BR-1, RGsS, SART3, STn, PAX5, OY-TES1, sperm protein 17, LCK, HMWMAA, AKAP-4, SSX2, XAGE 1, B7II3, legumain, TIE2, Page4, MAD-CT-1, FAP, MAD-CT-2, fos related antigen 1, CBX2,
[0197] 30
[0198] 4897-8742-6199, V 1CLDN6, SPANX, TPTE, ACTL8, ANKRD30A, CDKN2A, MAD2L1, CTAG1B, SUNC1, LRRN1 and idiotype.
[0199] Antigens may include epitopic regions or epitopic peptides derived from genes mutated in tumor cells or from genes transcribed at different levels in tumor cells compared to normal cells, such as telomerase enzyme, survivin, mesothelin, mutated ras, bcr / abl rearrangement, Her2 / neu, mutated or wild-type p53, cytochrome P450 1B1, and abnormally expressed intron sequences such as N-acetylglucosaminyltransferase-V: clonal rearrangements of immunoglobulin genes generating unique idiotypes in myeloma and B-cell lymphomas; tumor antigens that include epitopic regions or epitopic peptides derived from oncoviral processes, such as human papilloma virus proteins E6 and E7; Epstein bar virus protein LMP2; nonmutated oncofetal proteins with a tumor-selective expression, such as carcinoembryonic antigen and alpha-fetoprotein.
[0200] Antigen-presenting cells (APCs), which include macrophages, B lymphocytes, and dendritic cells, are distinguished by their expression of a particular MHC molecule. APCs internalize antigen and re-express a part of that antigen, together with the MHC molecule on their outer cell membrane. The MHC is a large genetic complex with multiple loci. The MHC loci encode two major classes of MHC membrane molecules, referred to as class I and class II MHCs. T helper lymphocytes generally recognize antigen associated with MHC class II molecules, and T cytotoxic lymphocytes recognize antigen associated with MHC class I molecules. In humans the MHC is referred to as the HLA complex and in mice the H-2 complex.
[0201] In some cases, artificial APCs (aAPCs) are useful in preparing therapeutic compositions and cell therapy products of the embodiments. For general guidance regarding the preparation and use of antigen-presenting systems, see, e.g., U. S. Patent Nos. 6,225,042, 6,355,479, 6,362,001 and 6,790,662.
[0202] aAPC systems may comprise at least one exogenous assisting molecule. Any suitable number and combination of assisting molecules may be employed. The assisting molecule may be selected from assisting molecules such as co-stimulatory molecules and adhesion molecules. Exemplary co-stimulatory molecules include CD86, CD64 (FcyRI), 41BB ligand, and IL-21. Adhesion molecules may include carbohydrate-binding glycoproteins such as selectins, transmembrane binding glycoproteins such as integrins, calcium-dependent proteins such as cadherins, and single-pass transmembrane immunoglobulin (Ig) superfamily proteins, such as intercellular adhesion molecules (ICAMs), which promote, for example, cell-to-cell or cell-to-
[0203] 31
[0204] 4897-8742-6199, V 1matrix contact. Exemplary adhesion molecules include LFA-3 and ICAMs, such as ICAM- 1. Techniques, methods, and reagents useful for selection, cloning, preparation, and expression of exemplary assisting molecules, including co-stimulatory molecules and adhesion molecules, are exemplified in, e.g., U. S. Patent Nos. 6,225,042, 6,355,479, and 6,362,001.
[0205] CAR T cell application. Peripheral blood mononuclear cells (PBMCs) may be obtained through leukapheresis, in which whole blood is withdrawn from a subject and mononuclear cells are separated using centrifugation-based leukapheresis procedures, after which remaining blood components are returned to the subject. The collected cell population typically comprises T lymphocytes along with B cells, natural killer (NK) cells, and monocytes. T cells may subsequently be enriched from the collected PBMC population using methods known in the art, including immunomagnetic selection based on cell surface markers such as CD3, CD4, or CD8, fluorescence-activated cell sorting, density gradient separation, or other cell isolation techniques.
[0206] Following isolation or enrichment, the T cells are generally activated to induce proliferation and render the cells receptive to genetic modification. Activation may be accomplished by exposure to agents that stimulate the T cell receptor complex and associated co-stimulatory pathways. For example, T cells may be activated using antibodies directed against CD3 and CD28, artificial antigen-presenting cells, ligand-expressing feeder cells, or bead-based activation reagents. Activation may be carried out in cell culture media containing nutrients and growth factors suitable for maintaining T cell viability and proliferation.
[0207] Activated T cells are subsequently genetically modified to express a chimeric antigen receptor (CAR). The CAR typically comprises an extracellular antigen-binding domain capable of recognizing a selected antigen expressed on the surface of a target cell, a hinge or spacer region, a transmembrane domain that anchors the receptor in the cell membrane, and one or more intracellular signaling domains capable of initiating T cell activation upon antigen binding. The antigen-binding domain may comprise, for example, a single-chain variable fragment (scFv) derived from an antibody that recognizes the selected antigen. Intracellular signaling domains commonly include the CD3ζ signaling module and may further include co-stimulatory signaling domains such as CD28, 4- IBB (CD 137), ICOS, 0X40, or combinations thereof. CAR constructs may correspond to first-generation, second-generation, third-generation, or later CAR designs incorporating one or more costimulatory signaling domains.
[0208] Genetic modification of the T cells may be accomplished using viral or non-viral gene delivery systems. Viral vectors suitable for introducing nucleic acids encoding the CAR include
[0209] 32
[0210] 4897-8742-6199, V 1retroviral vectors and lentiviral vectors that integrate the genetic construct into the genome of the T cell. Non-viral delivery methods may also be employed, including electroporation of DNA or RNA constructs, transposon-based systems such as Sleeping Beauty or PiggyBac, or genome-editing systems capable of directing insertion of a CAR-encoding sequence into a selected genomic locus. Following gene transfer, a population of T cells expressing the CAR is obtained.
[0211] After genetic modification, the engineered T cells are cultured ex vivo under conditions that promote proliferation and expansion of the CAR-expressing population. Expansion may be performed in culture vessels, gas-permeable culture bags, stirred bioreactors, or other closed or semi-closed cell culture systems designed for clinical manufacturing. The culture medium may include cytokines that support T cell growth and survival, including interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin- 15 (IL- 15), interleukin-21 (IL-21), or combinations thereof. During the expansion phase, the cells may be monitored for viability, proliferation rate, phenotype, and expression of the CAR. Expansion continues until the cell population reaches a therapeutically effective quantity and meets predetermined release criteria suitable for therapeutic use.
[0212] Prior to completion of the manufacturing process, the engineered T cell product may undergo quality control testing to confirm that the product meets predetermined release criteria. Such testing may include sterility testing, endotoxin detection, assessment of cell viability, measurement of CAR expression levels, and evaluation for the presence of replication-competent viral vectors where viral gene transfer methods have been used. Following completion of quality control testing, the cells may be washed, concentrated, and formulated in an appropriate infusion or cryopreservation medium.
[0213] The resulting engineered T cell composition constitutes a CAR-T cell product comprising a population of T cells genetically modified to express the CAR and expanded to a therapeutically effective quantity suitable for clinical use. In certain manufacturing procedures the final product may be cryopreserved using a clinically compatible cryopreservation solution and stored at low temperature, for example in liquid nitrogen, until use.
[0214] Tumor-infiltrating lymphocyte (TIL) therapy application. TILs are obtained from tumor tissue collected from a subject, for example from one or more primary or metastatic lesions surgically resected from the subject. The resected tumor tissue is mechanically and / or enzymatically dissociated to release lymphocytes present within the tumor microenvironment. The resulting cell population, which includes tumor-infiltrating lymphocytes, may be cultured
[0215] 33
[0216] 4897-8742-6199, V 1under conditions that support T-cell survival and proliferation. In many manufacturing processes, small fragments of tumor tissue or dissociated tumor cell suspensions are placed in culture media supplemented with interleukin-2 (IL- 2) to promote outgrowth and expansion of TIL populations. Initial expansion is typically carried out for approximately two to four weeks or until sufficient lymphocyte growth is observed.
[0217] Following the initial outgrowth phase, the TIL population may undergo a rapid expansion phase in which the cells are further stimulated and expanded to increase cell numbers suitable for therapeutic use. Stimulation may be performed using reagents that activate the T cell receptor complex and associated co-stimulatory pathways. For example, stimulation may be carried out using antibodies directed against CD3 and CD28, anti-CD3 antibody in the presence of accessory cells, irradiated allogeneic peripheral blood mononuclear cells, or other comparable activating reagents known in the art. The stimulated TIL population is then expanded under conditions that promote proliferation of activated lymphocytes.
[0218] Expansion may be performed in culture vessels or systems suitable for large-scale lymphocyte culture, including gas-permeable culture bags, culture flasks, rocking platform bioreactors, or other cell culture systems used for clinical cell therapy manufacturing. Culture media may be supplemented with cytokines that support T cell proliferation and survival, including interleukin-2 and, in certain cases, additional cytokines such as IL-7, IL- 15, or combinations thereof. The expansion phase is typically carried out for approximately 10 to 14 days or until the lymphocyte population reaches a therapeutically effective quantity.
[0219] During culture, the TIL population may be monitored for cell viability, proliferation rate, phenotype, and functional activity. Prior to completion of the manufacturing process, the expanded TIL product may undergo quality control testing to confirm that the product meets predetermined release criteria. Such testing may include sterility testing, endotoxin detection, and assessment of cell viability and phenotype.
[0220] Following expansion and quality control evaluation, the TIL population may be harvested, washed, and concentrated. The resulting cell composition constitutes a TIL therapy product comprising a population of tumor-infiltrating lymphocytes expanded ex vivo to a therapeutically effective quantity. The final product may be formulated in an infusion medium suitable for clinical administration or cryopreserved using a clinically compatible cryopreservation solution and stored at low temperature, for example in liquid nitrogen, until use.
[0221] 34
[0222] 4897-8742-6199, V 1Biomanufacturing and drug payload delivery application. PBMCs may be collected from a subject by leukapheresis and processed according to standard lymphocyte manufacturing procedures. Peripheral blood mononuclear cells obtained from the leukapheresis product may be enriched for T lymphocytes using methods known in the art, including immunomagnetic selection based on cell surface markers such as CD3, density gradient separation, or other cell isolation techniques. The resulting T cell population is stimulated using reagents that activate the T cell receptor complex and associated costimulatory pathways, for example beads coated with anti-CD3 and anti-CD28 antibodies, artificial antigen-presenting cells, or other activating reagents suitable for inducing T cell proliferation.
[0223] Following activation, the cells are genetically modified to express a target transgene encoding a therapeutic protein, biologic molecule, or other functional payload. Gene delivery may be performed using methods commonly employed in cell engineering. Viral gene delivery systems may include lentiviral vectors, γ-retroviral vectors, adenoviral vectors, or adeno-associated viral (AAV) vectors capable of introducing nucleic acids encoding the transgene into the cells. Non-viral gene delivery techniques may also be used, including electroporation of plasmid DNA or messenger RNA, transposon-based systems such as Sleeping Beauty or PiggyBac, lipid nanoparticle-mediated nucleic acid delivery, or other physical or chemical transfection methods known in the art. Following gene delivery, the cells are cultured under conditions that promote survival, expression of the introduced transgene, and expansion of the modified lymphocyte population.
[0224] Expansion may be performed using culture systems suitable for large-scale lymphocyte culture, including culture flasks, gas-permeable culture bags, stirred bioreactors, rocking platform bioreactors, or other closed or semi-closed cell culture systems used in cellular manufacturing. The culture medium may be supplemented with cytokines that support T cell proliferation and viability, including interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin- 15 (IL-15), interleukin-21 (IL-21), or combinations thereof. During the expansion phase, the cells may be monitored for viability, proliferation rate, phenotype, and expression of the introduced transgene.
[0225] For biomanufacturing applications, the engineered lymphocytes may be maintained in culture for extended periods under conditions that support continued cell growth and production of the encoded protein. In certain manufacturing processes, the cells may be periodically stimulated using activating reagents that engage the T cell receptor complex and
[0226] 35
[0227] 4897-8742-6199, V 1associated co-stimulatory pathways to sustain proliferation and maintain production of the transgene product. Culture supernatants containing the expressed protein may be collected at defined intervals and subjected to purification using standard protein purification methods known in the art.
[0228] For cell-based delivery applications, the engineered lymphocytes may be expanded for a defined period, for example approximately 8 to 10 days, until the cell population reaches a therapeutically effective quantity. During this manufacturing process, the cells may undergo quality control testing to confirm that the product meets predetermined release criteria. Such testing may include sterility testing, endotoxin detection, assessment of cell viability, and evaluation of transgene expression.
[0229] Following expansion and quality control evaluation, the engineered cell population may be harvested, washed, and concentrated. The resulting cell composition constitutes a cell therapy product comprising lymphocytes engineered to express the transgene payload. The final product may be formulated in an appropriate infusion or cryopreservation medium. In certain manufacturing workflows, the cells may be cryopreserved using a clinically compatible cryopreservation solution and stored at low temperature, for example in liquid nitrogen, until use.
[0230] III. Cell Engineering
[0231] A. Expression Constructs
[0232] According to the disclosure there are provided engineered vectors that facilitate expression of CAR constructs. Such expression vectors contain elements coding for the nonantigen binding portions of CARs along with cis-acting regulatory elements. The expression vector of some embodiments of the disclosure includes additional sequences which render this vector suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., as a shuttle vector). In addition, typical cloning vectors may also contain a transcription and translation initiation sequence, transcription and translation terminator and a poly adenylation signal. The nucleic acid construct of some embodiments of the disclosure includes a signal sequence for secretion or presentation of the binding agent from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence.
[0233] Eukaryotic promoters typically contain two types of recognition sequences, the TATA box and upstream promoter elements. The TATA box, located 25-30 base pairs upstream of 36
[0234] 4897-8742-6199, V 1the transcription initiation site, is thought to be involved in directing RNA polymerase to begin RNA synthesis. The other upstream promoter elements determine the rate at which transcription is initiated. Preferably, the promoter utilized by the expression vector is active in the specific cell population transformed. Examples of cell type-specific and / or tissue- specific promoters include promoters such as albumin that is liver specific (Pinkert et al., Genes Dev.
[0235] 1:268-277 (1987)), lymphoid specific promoters (Calame et al., Adv. Immunol. 43:235-275 (1988)); in particular promoters of T-cell receptors (Winoto etal., EMBO J. 8:729-733 (1989)) and immunoglobulins; (Banerji etal., Cell 33:729-740 (1983)), neuron-specific promoters such as the neurofilament promoter (Byrne etal., Proc. Natl. Acad. Sci. USA 86:5473-5477 (1989)), pancreas-specific promoters (Edlunch et al., Science 230:912-916 (1985)) or mammary glandspecific promoters such as the milk whey promoter (U. S. Pat. No. 4,873,316 and European Application Publication No. EP0264166). In the construction of the expression vector, the promoter is preferably positioned approximately the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art; however, some variation in this distance can be accommodated without loss of promoter function.
[0236] Enhancer elements can stimulate transcription up to 1,000-fold from linked homologous or heterologous promoters. Enhancers are active when placed downstream or upstream from the transcription initiation site. Many enhancer elements derived from viruses have a broad host range and are active in a variety of tissues. For example, the SV40 early gene enhancer is suitable for many cell types. Other enhancer / promoter combinations that are suitable for some embodiments of the disclosure include those derived from polyoma virus, human or murine cytomegalovirus (CMV), the long-term repeat from various retroviruses such as murine leukemia virus, murine or Rous sarcoma virus and HIV. See, Enhancers and Eukaryotic Expression, Cold Spring Harbor Press, Cold Spring Harbor, N. Y. 1983.
[0237] Polyadenylation sequences can also be added to the expression vector in order to increase the efficiency of TCRL mRNA translation. Two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are suitable for some embodiments of the disclosure include those derived from SV40.
[0238] In addition to the elements already described the expression vector of some embodiments of the disclosure may contain other specialized elements intended to increase the
[0239] 37
[0240] 4897-8742-6199, V 1level of expression of cloned nucleic acids or to facilitate the identification of cells that carry the recombinant DNA. For example, a number of animal viruses contain DNA sequences that promote the extra chromosomal replication of the viral genome in permissive cell types. Plasmids bearing these viral replicons are replicated episomally as long as the appropriate factors are provided by genes either carried on the plasmid or with the genome of the host cell.
[0241] The vector may or may not include a eukaryotic replicon. If a eukaryotic replicon is present, then the vector is amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is possible. Instead, the recombinant DNA integrates into the genome of the engineered cell, where the promoter directs expression of the desired nucleic acid.
[0242] Also provided are cells which comprise the polynucleotides / expression vectors as described herein. Such cells are typically selected for high expression of recombinant proteins (e.g., bacterial, plant or eukaryotic cells e.g., CHO, HEK-293 cells), but may also be host cells having a specific immune effector activity (e.g., T cells or NK cells, such as Jurkat cells) when for instance the CDRs of the TCRL are implanted in a T Cell Receptor or CAR transduced in said cells which are used in adoptive cell therapy.
[0243] Next, the CAR library is introduced into mammalian host cells that are then cultured under conditions supporting expression of encoded CARs. The host cells expressing the CAR are then contacted with target antigen positive host cells exhibiting CAR activation are then identified using a variety of different approaches. Once these cells are identified, the binding region can be sequenced and further developed.
[0244] B. Gene / Genome Editing
[0245] Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly insert genetic material into a host genome, genome editing targets the insertions to site-specific locations. The basic mechanism involved in genetic manipulations through programmable nucleases is the recognition of target genomic loci and binding of effector DNA-binding domain (DBD), double-strand breaks (DSBs) in target DNA by the restriction
[0246] 38
[0247] 4897-8742-6199, V 1endonucleases (Tok I and Cas), and the repair of DSBs through homology-directed recombination (HDR) or non-homologous end joining (NHEJ).
[0248] CRISPR. Recently, harnessing the bacterial immune system of CRISPR to perform on demand gene editing revolutionized the way scientists approach genomic editing. The Cas9 protein of the CRISPR system, which is an RNA guided DNA endonuclease, can be engineered to target new sites with relative ease by altering its guide RNA sequence. This discovery has made sequence specific gene editing functionally effective.
[0249] In general, “CRISPR system” refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a “direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a “spacer” in the context of an endogenous CRISPR system), and / or other sequences and transcripts from a CRISPR locus.
[0250] The CRISPR / Cas nuclease or CRISPR / Cas nuclease system can include a non-coding RNA molecule (guide) RNA, which sequence-specifically binds to DNA, and a Cas protein (e.g., Cas9), with nuclease functionality (e.g., two nuclease domains). One or more elements of a CRISPR system can derive from a type I, type II, or type III CRISPR system, e.g., derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.
[0251] The CRISPR system can induce double stranded breaks (DSBs) at the target site, followed by disruptions as discussed herein. In other embodiments, Cas9 variants, deemed “nickases,” are used to nick a single strand at the target site. Paired nickases can be used, e.g., to improve specificity, each directed by a pair of different gRNAs targeting sequences such that upon introduction of the nicks simultaneously, a 5' overhang is introduced. In other embodiments, catalytically inactive Cas9 is fused to a heterologous effector domain such as a transcriptional repressor (e.g., KRAB) or activator, to affect gene expression. Alternatively, a CRISPR system with a catalytically inactivate Cas9 further comprises a transcriptional repressor or activator fused to a ribosomal binding protein.
[0252] In some aspects, a Cas nuclease and gRNA (including a fusion of crRNA specific for the target sequence and fixed tracrRNA) are introduced into the cell. In general, target sites at the 5' end of the gRNA target the Cas nuclease to the target site, e.g., the gene, using complementary base pairing. The target site may be selected based on its location immediately
[0253] 39
[0254] 4897-8742-6199, V 15' of a protospacer adjacent motif (PAM) sequence, such as typically NGG, or NAG. In this respect, the gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence. Typically, “target sequence” generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex.
[0255] The target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. The target sequence may be located in the nucleus or cytoplasm of the cell, such as within an organelle of the cell. Generally, a sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an “editing template” or “editing polynucleotide” or “editing sequence.” In some aspects, an exogenous template polynucleotide may be referred to as an editing template. In some aspects, the recombination is homologous recombination.
[0256] Typically, in the context of an endogenous CRISPR system, formation of the CRISPR complex (comprising the guide sequence hybridized to the target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. The tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of the CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to the guide sequence. The tracr sequence has sufficient complementarity to a tracr mate sequence to hybridize and participate in formation of the CRISPR complex, such as at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
[0257] One or more vectors driving expression of one or more elements of the CRISPR system can be introduced into the cell such that expression of the elements of the CRISPR system direct formation of the CRISPR complex at one or more target sites. Components can also be delivered to cells as proteins and / or RNA. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate
[0258] 40
[0259] 4897-8742-6199, V 1regulatory elements on separate vectors. The Cas enzyme may be a target gene under the control of a regulated alternative splicing event, as disclosed herein, either as a chimeric target gene minigene or as a target gene for a chimeric minigene transactivator. The gRNA may be under the control of a constitutive promoter.
[0260] Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. The vector may comprise one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a “cloning site”). In some embodiments, one or more insertion sites are located upstream and / or downstream of one or more sequence elements of one or more vectors. When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
[0261] A vector may comprise a regulatory clement operably linked to an enzyme-coding sequence encoding the CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csx12), CaslO, Cas12a, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3. Csxl, Csxl5, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. These enzymes are known; for example, the amino acid sequence of 5. pyogenes Cas9 protein may be found in the SwissProt database under accession number Q99ZW2.
[0262] The CRISPR enzyme can be Cas9 (e.g., from S. pyogenes or. S. pneumoniae). The CRISPR enzyme can direct cleavage of one or both strands at the location of a target sequence, such as within the target sequence and / or within the complement of the target sequence. The vector can encode a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). In some embodiments, a Cas9 nickase may be used in combination with guide sequence(s), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce NHEJ or HDR.
[0263] 41
[0264] 4897-8742-6199, V 1In some embodiments, an enzyme coding sequence encoding the CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate. In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization.
[0265] In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of the CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
[0266] Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
[0267] The CRISPR enzyme may be part of a fusion protein comprising one or more heterologous protein domains. A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity,
[0268] 42
[0269] 4897-8742-6199, V 1transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-5- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that binds DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding-domain (DBD) fusions, GAL4A DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US 20110059502, incorporated herein by reference.
[0270] TALENs. Transcription activator-like effector nucleases (TALEN) are restriction enzymes that can be engineered to cut specific sequences of DNA. fhey are made by fusing a TAL effector DNA-binding domain to a DNA cleavage domain (a nuclease which cuts DNA strands). Transcription activator-like effectors (often referred to as TALEs, but not to be confused with the three amino acid loop extension homeobox class of proteins) are proteins secreted by some β- and γ-proteobacteria. Most of these are Xanthomonads. Plant pathogenic Xanthomonas bacteria are especially known for TALEs, produced via their type III secretion system. These proteins can bind promoter sequences in the host plant and activate the expression of plant genes that aid bacterial infection. They recognize plant DNA sequences through a central repeat domain consisting of a variable number of ~34 amino acid repeats. There appears to be a one-to-one correspondence between the identity of two critical amino acids in each repeat and each DNA base in the target sequence. These proteins are interesting to researchers both for their role in disease of important crop species and the relative ease of retargeting them to bind new DNA sequences. Similar proteins can be found in the pathogenic bacterium Ralstonia solanacearum and Burkholderia rhizoxinica, as well as yet unidentified marine microorganisms. The term TALE-likes is used to refer to the putative protein family encompassing the TALEs and these related proteins.
[0271] The most distinctive characteristic of TAL effectors is a central repeat domain containing between 1.5 and 33.5 repeats that are usually 34 residues in length (the C-terminal
[0272] 43
[0273] 4897-8742-6199, V 1repeat is generally shorter and referred to as a “half repeat”). A typical repeat sequence is LTPEQVVAIASHDGGKQALEl’VQRLLPVLCQAIIG (SEQ ID NO: 1), but the residues at the 12th and 13th positions are hypervariable (these two amino acids are also known as the repeat variable di-residue or RVD). There is a simple relationship between the identity of these two residues in sequential repeats and sequential DNA bases in the TAL effector's target site. The crystal structure of a TAL effector bound to DNA indicates that each repeat comprises two alpha helices and a short RVD-containing loop where the second residue of the RVD makes sequence-specific DNA contacts while the first residue of the RVD stabilizes the RVD-containing loop. Target sites of TAL effectors also tend to include a thymine flanking the 5’ base targeted by the first repeat; this appears to be due to a contact between this T and a conserved tryptophan in the region N-terminal of the central repeat domain. However, this "zero" position does not always contain a thymine, as some scaffolds are more permissive.
[0274] TAL effectors can induce susceptibility genes that are members of the N0DULIN3 (N3) gene family. These genes arc essential for the development of disease. In rice two genes, Os-8N3 and Os-11N3, are induced by TAL effectors. Os-8N3 is induced by PthXol and Os-11N3 is induced by PthXo3 and AvrXa7. Two hypotheses exist about possible functions for N3 proteins - first, that they are involved in copper transport, resulting in detoxification of the environment for bacteria (the reduction in copper level facilitates bacterial growth), and second, that they are involved in glucose transport, facilitating glucose flow (this mechanism provides nutrients to bacteria and stimulates pathogen growth and virulence).
[0275] This simple correspondence between amino acids in TAL effectors and DNA bases in their target sites makes them useful for protein engineering applications. Numerous groups have designed artificial TAL effectors capable of recognizing new DNA sequences in a variety of experimental systems. Such engineered TAL effectors have been used to create artificial transcription factors that can be used to target and activate or repress endogenous genes in tomato, Arabidopsis thaliana, and human cells.
[0276] Genetic constructs to encode TAL effector-based proteins can be made using either conventional gene synthesis or modular assembly. A plasmid kit for assembling custom TALEN and other TAL effector constructs is available through the public, not-for-profit repository Addgene. Webpages providing access to public software, protocols, and other resources for TAL effect or-DNA targeting applications include the TAL Effector-Nucleotide Targeter and taleffectors.com.
[0277] 44
[0278] 4897-8742-6199, V 1Engineered TAL effectors can also be fused to the cleavage domain of FokI to create TAL effector nucleases (TALEN) or to meganucleases (nucleases with longer recognition sites) to create "megaTALs." Such fusions share some properties with zinc finger nucleases and may be useful for genetic engineering and gene therapy applications. TALEN-based approaches are used in the emerging fields of gene editing and genome engineering. TALE-induced non-homologous end joining modification has been used to produce novel disease resistance in rice.
[0279] Zinc Finger DNA Binding Domains. A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions (Zn2+) to stabilize the fold. It was originally coined to describe the finger- like appearance of a hypothesized structure from the African clawed frog (Xenopus laevis) transcription factor IIIA. However, it has been found to encompass a wide variety of differing protein structures in eukaryotic cells. Xenopus laevis TFIIIA was originally demonstrated to contain zinc and require the metal for function in 1983, the first such reported zinc requirement for a gene regulatory protein followed soon thereafter by the Krüppel factor in Drosophila. It often appears as a metal-binding domain in multi-domain proteins.
[0280] Proteins that contain zinc fingers (zinc finger proteins) are classified into several different structural families. Unlike many other clearly defined supersecondary structures such as Greek keys or β hairpins, there are a number of types of zinc fingers, each with a unique three-dimensional architecture. A particular zinc finger protein's class is determined by this three-dimensional structure, but it can also be recognized based on the primary structure of the protein or the identity of the ligands coordinating the zinc ion. In spite of the large variety of these proteins, however, the vast majority typically function as interaction modules that bind DNA, RNA, proteins, or other small, useful molecules, and variations in structure serve primarily to alter the binding specificity of a particular protein.
[0281] Since their original discovery and the elucidation of their structure, these interaction modules have proven ubiquitous in the biological world and may be found in 3% of the genes of the human genome. In addition, zinc fingers have become extremely useful in various therapeutic and research capacities. Engineering zinc fingers to have an affinity for a specific sequence is an area of active research, and zinc finger nucleases and zinc finger transcription factors are two of the most important applications of this to be realized to date.
[0282] Zinc finger (Znf) domains are relatively small protein motifs that contain multiple finger-like protrusions that make tandem contacts with their target molecule. Some of these
[0283] 45
[0284] 4897-8742-6199, V 1domains bind zinc, but many do not, instead binding other metals such as iron, or no metal at all. For example, some family members form salt bridges to stabilize the finger-like folds. They were first identified as a DNA-binding motif in transcription factor TFIIIA from Xenopus laevis (African clawed frog), however they are now recognized to bind DNA, RNA, protein, and / or lipid substrates. Their binding properties depend on the amino acid sequence of the finger domains and on the linker between fingers, as well as on the higher-order structures and the number of fingers. Znf domains are often found in clusters, where fingers can have different binding specificities. Znf motifs occur in several unrelated protein superfamilies, varying in both sequence and structure. They display considerable versatility in binding modes, even between members of the same class (e.g., some bind DNA, others protein), suggesting that Znf motifs are stable scaffolds that have evolved specialized functions. For example, Znf-containing proteins function in gene transcription, translation, mRNA trafficking, cytoskeleton organization, epithelial development, cell adhesion, protein folding, chromatin remodeling, and zinc sensing, to name but a few. Zinc -binding motifs arc stable structures, and they rarely undergo conformational changes upon binding their target.
[0285] Initially, the term zinc finger was used solely to describe DNA-binding motif found in Xenopus laevis; however, it is now used to refer to any number of structures related by their coordination of a zinc ion. In general, zinc fingers coordinate zinc ions with a combination of cysteine and histidine residues. Originally, the number and order of these residues was used to classify different types of zinc fingers e.g., Cys2His2, Cys4, and Cys6). More recently, a more systematic method has been used to classify zinc finger proteins instead. This method classifies zinc finger proteins into "fold groups" based on the overall shape of the protein backbone in the folded domain. The most common "fold groups" of zinc fingers are the CyS2His2-like (the "classic zinc finger"), treble clef, and zinc ribbon.
[0286] Various protein engineering techniques can be used to alter the DNA-binding specificity of zinc fingers and tandem repeats of such engineered zinc fingers can be used to target desired genomic DNA sequences. Fusing a second protein domain such as a transcriptional activator or repressor to an array of engineered zinc fingers that bind near the promoter of a given gene can be used to alter the transcription of that gene. Fusions between engineered zinc finger arrays and protein domains that cleave or otherwise modify DNA can also be used to target those activities to desired genomic loci. The most common applications for engineered zinc finger arrays include zinc finger transcription factors and zinc finger nucleases, but other applications have also been described. Typical engineered zinc finger
[0287] 46
[0288] 4897-8742-6199, V 1arrays have between 3 and 6 individual zinc finger motifs and bind target sites ranging from 9 base pairs to 18 base pairs in length. Arrays with 6 zinc finger motifs are particularly attractive because they bind a target site that is long enough to have a good chance of being unique in a mammalian genome.
[0289] IV. Treatment of Cancers
[0290] In accordance with the present disclosure, provided are methods of treating cancers, particularly solid cancers. The methods involve the administration of CAR T cells to a subject such at the cells are brought in proximity with a cancer cell / cancer cell environment and their therapeutic effect is delivered. These methods can also be applied to other lymphocyte-based therapies where the NAD(P)H low and high populations would have distinct benefits. In the case of CAR T and other adoptive lymphocyte therapies, the NAD(P)H low cells have a profile that is consistent with what has been seen as therapeutically beneficial (slow dividing, long lasting, and resistant to dysregulation caused by chronic signaling). On the other hand, the NAD(P)H high cells would have benefit in situations where rapid expansion and contraction of therapeutic lymphocytes would be advantageous, such as the delivery of drug payloads using lymphocytes or in the biomanufacturing of therapeutic molecules. The administration may be performed multiple times (2, 3, 4, 5, 6, 7, 8, 9, 10 or more) to a subject as needed. The subject may be an infant, a pediatric patient, a juvenile, a young adult, and adult or a senior. The subject may be a human, male or female, or may be a non-human mammal.
[0291] In certain aspects the cancer tumor is a renal cell cancer, melanoma, prostate cancer, chronic lymphocytic leukemia, bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, g astrointestine, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma;
[0292] 47
[0293] 4897-8742-6199, V 1acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w / squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; androblastoma, malignant; sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extramammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malig melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma: fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant: mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides;
[0294] 48
[0295] 4897-8742-6199, V 1other specified non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia.
[0296] A. Pharmaceutical Formulations and Routes of Administration Pharmaceutical compositions provided herein comprise an effective amount of one or more therapeutic compositions and, optionally, an additional agent dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains a therapeutic nucleic acid construct or a therapeutic engineered cell and one or more excipients will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.
[0297] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absoiption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is contemplated.
[0298] In certain embodiments, the pharmaceutical composition may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it needs to be sterile for such routes of administration as injection. In certain embodiments, pharmaceutical compositions provided herein can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially,
[0299] 49
[0300] 4897-8742-6199, V 1intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, topically, locally, inhalation (e.g. aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference).
[0301] In certain embodiments, the actual dosage amount of a composition administered to a patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. The practitioner responsible for administration will, in any event, determine the concentration of active ingrcdicnt(s) in a composition and appropriate dose(s) for the individual subject.
[0302] In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1% of an active compound. In other embodiments, the active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. In other non-limiting examples, a dose may also comprise from about 1 microgram / kg / body weight, about 5 microgram / kg / body weight, about 10 microgram / kg / body weight, about 15 microgram / kg / body weight, about 20 microgram / kg / body weight, about 25 microgram / kg / body weight, about 30 microgram / kg / body weight, about 35 microgram / kg / body weight, about 0.04 milligram / kg / body weight, about 0.05 milligram / kg / body weight, about 0.06 milligram / kg / body weight, about 0.07 milligram / kg / body weight, about 0.08 milligram / kg / body weight, about 0.09 milligram / kg / body weight, about 0.1 milligram / kg / body weight, about 0.2 milligram / kg / body weight, to about 0.5 mg / kg / body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 0.01 mg / kg / body weight to about 0.1 mg / kg / body weight, about 0.04 microgram / kg / body weight to about 0.08 milligram / kg / body weight, etc., can be administered, based on the numbers described above.
[0303] In any case, the composition may comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be
[0304] 50
[0305] 4897-8742-6199, V 1brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
[0306] In embodiments where the composition is in a liquid form, a carrier can be a solvent or dispersion medium comprising but not limited to, water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes) and combinations thereof. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example liquid polyol or lipids; by the use of surfactants such as, for example hydroxypropylcellulose; or combinations thereof such methods. In many cases, it will be preferable to include isotonic agents, such as, for example, sugars, sodium chloride or combinations thereof.
[0307] In other embodiments, one may use eye drops, nasal solutions or sprays, aerosols or inhalants in the present embodiments. Such compositions are generally designed to be compatible with the target tissue type. In a non-limiting example, nasal solutions are usually aqueous solutions designed to be administered to the nasal passages in drops or sprays. Nasal solutions are prepared so that they are similar in many respects to nasal secretions, so that normal ciliary action is maintained. Thus, in preferred embodiments the aqueous nasal solutions usually are isotonic or slightly buffered to maintain a pH of about 5.5 to about 6.5. In addition, antimicrobial preservatives, similar to those used in ophthalmic preparations, drugs, or appropriate drug stabilizers, if required, may be included in the formulation. For example, various commercial nasal preparations are known and include drugs such as antibiotics or antihistamines.
[0308] Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and / or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose. The
[0309] 51
[0310] 4897-8742-6199, V 1preparation of highly concentrated compositions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small area.
[0311] The composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng / mg protein.
[0312] In particular embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.
[0313] B. Combination Therapies
[0314] In order to increase the effectiveness of a T lymphocyte (e.g., CAR T cell) therapy of the present disclosure, it may be desirable to combine this therapy with other agents effective in the treatment of the disease of interest. As a non-limiting example, the treatment of cancer may be implemented with a CAR / CAR T cell of the present disclosure along with other anticancer agents, including CD4+ T lymphocyte. An “anti-cancer” agent is capable of negatively affecting cancer in a subject, for example, by killing cancer cells, inducing apoptosis in cancer cells, reducing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the blood supply to a tumor or cancer cells, promoting an immune response against cancer cells or a tumor, preventing or inhibiting the progression of cancer, or increasing the lifespan of a subject with cancer. In the case of a CD4+ T lymphocyte, this cell would provide exogenous IL-2 that may be lacking in the CAR T cell. More generally, these other compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell. This process may involve contacting the cells with the CAR / CAR T cell and the other agent(s) or factor(s) at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the CAR / CAR T cell and the other includes the second agent(s).
[0315] Treatment with the CAR / CAR T cell may precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agent and the anti-cancer peptide or nanoparticle complex are applied separately to the cell, one would
[0316] 52
[0317] 4897-8742-6199, V 1generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent and the anti-cancer peptide or nanoparticle complex would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one may contact the cell with both modalities within about 12-24 hours of each other and, more preferably, within about 6-12 hours of each other. In some situations, it may be desirable to extend the time period for treatment significantly where several days (e.g., 2, 3, 4, 5, 6 or 7 days) to several weeks (e.g., 1, 2, 3, 4, 5, 6, 7 or 8 weeks) lapse between the respective administrations.
[0318] Various combinations may be employed, where the CAR / CAR T cell therapy is “A” and the other agent is “B”:
[0319] A / B / A B / A / B B / B / A A / A / B A / B / B B / A / A A / B / B / B B / A / B / B B / B / B / A B / B / A / B A / A / B / B A / B / A / B A / B / B / A B / B / A / A B / A / B / A B / A / A / B A / A / A / B B / A / A / A A / B / A / A A / A / B / A In certain embodiments, administration of the CAR / CAR T cell therapy and / or other agent(s) to a patient will follow general protocols for the administration of chemotherapeutics, taking into account the toxicity, if any, of the vector. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, may be applied in combination with the described hyperproliferative cell therapy.
[0320] CD4+ Lymphocytes. The T helper cells (Th cells), also known as CD4+cells or CD4-positive cells, are a type of T cell that play an important role in the adaptive immune system. They aid the activity of other immune cells by releasing cytokines. They are considered essential in B cell antibody class switching, breaking cross -tolerance in dendritic cells, in the activation and growth of cytotoxic T cells, and in maximizing bactericidal activity of phagocytes such as macrophages and neutrophils. CD4+cells are mature Th cells that express the surface protein CD4. Genetic variation in regulatory elements expressed by CD4+cells determines susceptibility to a broad class of autoimmune diseases.
[0321] Th cells contain and release cytokines to aid other immune cells. Cytokines are small protein mediators that alter the behavior of target cells that express receptors for those cytokines. These cells help polarize the immune response depending on the nature of the immunological insult (for example; virus vs. extracellular bacterium vs. intracellular bacterium vs. helminth vs. fungus vs. protist).
[0322] 53
[0323] 4897-8742-6199, V 1Mature Th cells express the surface protein CD4 and are referred to as CD4+T cells. CD4+T cells are generally treated as having a pre-defined role as helper T cells within the immune system. For example, when an antigen-presenting cell displays a peptide antigen on MHC class II proteins, a CD4+cell will aid those cells through a combination of cell-to-cell interactions (e.g., CD40 (protein) and CD40L) and through cytokines.
[0324] Th cells are not a monolithic immunological entity because they are diverse in terms of function and their interaction with partner cells. In general, mature naive T cells are stimulated by professional antigen presenting cells to acquire an effector function. These are defined by the presence of a lineage-determining (or lineage-specifying) transcription factor (also called master regulator, though the term has been criticized for being too reductive). The loss of function in a lineage specifying transcription factor results in the absence of the corresponding class of helper T cell which can be devastating for the health of the host.
[0325] Following activation, the T helper cell (Th) then allows itself to proliferate. It achieves this by releasing a potent T cell growth factor called interleukin 2 (IL-2) which acts upon itself in an autocrine fashion. Activated T cells also produce the alpha sub-unit of the IL-2 receptor (CD25 or IL-2R), enabling a fully functional receptor that can bind with IL-2, which in turn activates the T cell's proliferation pathways.
[0326] The autocrine or paracrine secretion of IL-2 can bind to that same Th cell or neighboring Th's via the IL-2R, thereby driving proliferation and clonal expansion. The Th cells receiving both signals of activation and proliferation will then become ThO (T helper 0) cells that secrete IL-2, IL-4 and interferon gamma (IFN-y). The ThO cells will then differentiate into Thl or Th2 cells depending on cytokine environment. IFN-y drives Thl cell production while IL-10 and IL-4 inhibit Thl cell production. Conversely, IL-4 drives Th2 cell production and IFN-y inhibits Th2 cells. These cytokines are pleiotropic and carry out many other functions of the immune response.
[0327] Chemotherapy. Cancer therapies also include a variety of combination therapies. In some aspects, a CAR / CAR T cell therapeutic and / or an immune checkpoint inhibitor of the embodiments is administered (or formulated) in conjunction with a chemotherapeutic agent. For example, in some aspects, the chemotherapeutic agent is a protein kinase inhibitor such as a EGFR, VEGFR, AKT, Erbl, Erb2, ErbB, Syk, Bcr-Abl, JAK, Src, GSK-3, PI3K, Ras, Raf, MAPK, MAPKK, mTOR, c-Kit, eph receptor or BRAF inhibitors. Nonlimiting examples of protein kinase inhibitors include Afatinib, Axitinib, Bevacizumab, Bosutinib, Cetuximab, Crizotinib, Dasatinib, Erlotinib, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib,
[0328] 54
[0329] 4897-8742-6199, V 1Mubritinib. Nilotinib, Panitumumab, Pazopanib, Pegaptanib, Ranibizumab, Ruxolitinib, Saracatinib, Sorafenib, Sunitinib, Trastuzumab, Vandetanib, AP23451, Vemurafenib, MK-2206, GSK690693, A-443654, VQD-002, Miltefosine, Perifosine, CAL101, PX-866, LY294002, rapamycin, temsirolimus, everolimus, ridaforolimus, Alvocidib, Genistein, Selumetinib, AZD-6244, Vatalanib, P1446A-05, AG-024322, ZD1839, P276-00, GW572016 or a mixture thereof.
[0330] Yet further combination chemotherapies include, for example, alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall; dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores, aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholinodoxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5 -fluorouracil (5-FU); folic acid analogues such as denopterin, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine,
[0331] 55
[0332] 4897-8742-6199, V 16-azauridine, cannofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2”-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; taxoids, e.g., paclitaxel and docetaxel gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; carboplatin, procarbazine, plicomycin. gemcitabien, navelbine, famesyl-protein tansferase inhibitors, transplatinum, and pharmaceutically acceptable salts, acids or derivatives of any of the above. In certain embodiments, the compositions provided herein may be used in combination with gefitinib. In other embodiments, the present embodiments may be practiced in combination with Gleevac (e.g., from about 400 to about 800 mg / day of Gleevac may be administered to a patient). In certain embodiments, one or more chemotherapeutics may be used in combination with the compositions provided herein.
[0333] Radiotherapy. Other factors that cause DNA damage and have been used extensively include what are commonly known as y-rays, X-rays, and / or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors induce a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-
[0334] 56
[0335] 4897-8742-6199, V 1life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
[0336] The terms “contacted” and “exposed,” when applied to a cell, are used herein to describe the process by which a therapeutic composition and a chemotherapeutic or radiotherapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing.
[0337] Immunotherapy. Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.
[0338] Immunotherapy, thus, could be used as part of a combined therapy, in conjunction with a CAR / CAR T cell therapy of the present embodiments. The general approach for combined therapy is discussed below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present embodiments. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p 155.
[0339] Gene Therapy. In yet another embodiment, the secondary treatment is a gene therapy in which a therapeutic polynucleotide is administered before, after, or at the same time as the therapeutic composition. Viral vectors for the expression of a gene product are well known in the art, and include such eukaryotic expression systems as adenoviruses, adeno- associated viruses, retroviruses, herpesviruses, lentiviruses, poxviruses including vaccinia viruses, and papiloma viruses, including SV40. Alternatively, the administration of expression constructs can be accomplished with lipid-based vectors such as liposomes or DOTAP:cholesterol vesicles. All of these methods are well known in the art (see, e.g.. Sambrook et al., 1989; Ausubel et al., 1998; Ausubel, 1996).
[0340] 57
[0341] 4897-8742-6199, V 1Delivery of a vector encoding one of the following gene products will have a combined anti-hyperproliferative effect on target tissues. A variety of proteins are encompassed within the present embodiments, some of which are described below.
[0342] As noted above, the tumor suppressor oncogenes function to inhibit excessive cellular proliferation. The inactivation of these genes destroys their inhibitory activity, resulting in unregulated proliferation.
[0343] Genes that may be employed as secondary treatment in accordance with the present embodiments include p53, p16, Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MFN-II, zacl, p73, VHL, MMAC1 / PTEN, DBCCR-1, FCC, rsk-3, p27, p27 / pl6 fusions, p21 / p27 fusions, anti-thrombotic genes (e.g., COX-1, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb,fms, trk, ret, gsp, list, abl, E1A, p300, genes involved in angiogenesis (e.g., VEGF, FGF, thrombospondin, BAI-1, GDAIF, or their receptors), MCC and other genes listed in Table IV.
[0344] Apoptosis, or programmed cell death, is an essential process for normal embryonic development, maintaining homeostasis in adult tissues, and suppressing carcinogenesis (Kerr et al., 1972). The Bcl-2 family of proteins and ICE-like proteases have been demonstrated to be important regulators and effectors of apoptosis in other systems. The Bcl-2 protein, discovered in association with follicular lymphoma, plays a prominent role in controlling apoptosis and enhancing cell survival in response to diverse apoptotic stimuli (Bakhshi et al., 1985; Cleary and Sklar, Proc. Nat’l. Acad. Sci. USA, 82(21);7439-43, 1985; Cleary et al., 1986; Tsujimoto et al., 1985; Tsujimoto and Croce, 1986). The evolutionarily conserved Bcl-2 protein now is recognized to be a member of a family of related proteins, which can be categorized as death agonists or death antagonists.
[0345] Subsequent to its discovery, it was shown that Bcl-2 acts to suppress cell death triggered by a variety of stimuli. Also, it now is apparent that there is a family of Bcl-2 cell death regulatory proteins which share in common structural and sequence homologies. These different family members have been shown to either possess similar functions to Bcl-2 (e.g., BCIXL, Bclw, Bcls, Mcl-1, Al, Bfl-1 ) or counteract Bcl-2 function and promote cell death (e.g., Bax, Bak, Bik, Bim, Bid, Bad, Harakiri).
[0346] Surgery. Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative and palliative surgery. Curative surgery is a cancer treatment that may be used in conjunction with other therapies, such as the treatments provided herein, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy and / or alternative therapies.
[0347] 58
[0348] 4897-8742-6199, V 1Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and / or destroyed. Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and miscopically controlled surgery (Mohs’ surgery). It is further contemplated that the present embodiments may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue.
[0349] Upon excision of part of all of cancerous cells, tissue, or tumor, a cavity may be formed in the body. Treatment may be accomplished by perfusion, direct injection or local application of the area with an additional anti-cancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may be of varying dosages as well.
[0350] Anti-Inflammatory Agents. In certain aspects CAR / CAR T cell therapies and / or an immune checkpoint inhibitor are administered in conjuction with an anti-inflammatory agent. An anti-inflammatory agent is defined herein to refer to an agent that is known or suspected to be of benefit in the treatment or prevention of inflammation in a subject. Corticosteroids are a major class of anti-inflammatory agent. The corticosteroids may be short, medium, or long acting, and may be delivered in a variety of methods. A non-limiting list of corticosteroids contemplated in the present embodiments include the oral corticosteroids such as: cortisone, hydrocortisone, prednisone, and dexamethasone.
[0351] Another major class of anti-inflammatory agents are non-steroidal anti-inflammatory agents. Non-steroidal anti-inflammatory agents include a class of drugs used in the treatment of inflammation and pain. The exact mode of action of this class of drugs is unknown. Examples of members of this class of agents include, but are not limited to, ibuprofen, ketoprofen, flurbiprofen, nabumetone, piroxicam, naproxen, diclofenac, indomethacin, sulindac, tolmetin, etodolac, flufenamic acid, diflunisal, oxaprozin, rofecoxib, and celecoxib. One of ordinary skill in the art would be familiar with these agents. Included in this category are salicylates and derivates of salicylates, such as acetyl salicylic acid, sodium salicylate, choline salicylate, choline magnesium salicylate and diflunisal.
[0352] Other anti-inflammatory agents include anti-rheumatic agents, such as gold salts (e.g., gold sodium thiomalate, aurothioglucose, and auranofin), anti-rheumatic agents (e.g., chloroquine, hydroxychloroquine, and penicillamine), antihistamines (e.g., diphenhydramine, chlorpheniramine, clemastine, hydroxyzine, and triprolidine), and immunosuppressive agents (e.g., methotrexate, mechlorethamine, cyclophosphamide, chlorambucil, cyclosporine, and
[0353] 59
[0354] 4897-8742-6199, V 1azathioprine). Other immunosuppressive agents contemplated by the present embodiments is tacrolimus and everolimus. Tacrolimus suppresses interleukin-2 production associated with T-cell activation, inhibits differentiation and proliferation of cytotoxic T cells. Today, it is recognized worldwide as the cornerstone of immunosuppressant therapy. One of ordinary skill in the art would be familiar with these agents, and other members of this class of agents, as well as the mechanism of actions of these agents and indications for use of these agents.
[0355] Other agents. It is contemplated that other agents may be used in combination with the compositions provided herein to improve the therapeutic efficacy of treatment. These additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adehesion, or agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers. Immunomodulatory agents include tumor necrosis factor; interferon alpha, beta, and gamma; IL-2 and other cytokines; F42K and other cytokine analogs; or MIP-1, MIP-lbeta, MCP-1, RANTES, and other chemokines. It is further contemplated that the upregulation of cell surface receptors or their ligands such as Fas / Fas ligand, DR4 or DR5 / TRAIL would potentiate the apoptotic inducing abililties of the compositions provided herein by establishment of an autocrine or paracrine effect on hyperproliferative cells. Increases intercellular signaling by elevating the number of GAP junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population. In other embodiments, cytostatic or differentiation agents can be used in combination with the compositions provided herein to improve the anti-hyerproliferative efficacy of the treatments. Inhibitors of cell adhesion are contemplated to improve the efficacy of the disclosed agents and methods. Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with the compositions provided herein to improve the treatment efficacy.
[0356] In certain embodiments, hormonal therapy may also be used in conjunction with the present embodiments or in combination with any other cancer therapy previously described. The use of hormones may be employed in the treatment of certain cancers such as breast, prostate, ovarian, or cervical cancer to lower the level or block the effects of certain hormones such as testosterone or estrogen. This treatment is often used in combination with at least one other cancer therapy as a treatment option or to reduce the risk of metastases.
[0357] 60
[0358] 4897-8742-6199, V 1V. Examples
[0359] The following examples are included to demonstrate particular embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of embodiments, and thus can be considered to constitute particular modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
[0360] Example 1
[0361] The inventors conducted an in vivo genome-scale CRISPR KO screen to identify regulators of human CAR T cell intratumoral persistence. This was enabled through compact CRISPR / Cas12a-based screening, which reduces guide library size by approximately fourfold compared to typical CRISPR / Cas9-based approaches, facilitating in vivo applications. To perform the screen, primary human T cells were transduced with Cas12a, guide library, and HER2.41BB CAR. After in vitro expansion and guide4-cell selection, CAR T cells were infused into 143B human osteosarcoma-bearing mice. After approximately 2.5 weeks, tumors were harvested and tumor infiltrating T cells were sequenced to determine guide enrichment and depletion. Follow-up validation experiments utilized the same osteosarcoma cell line and HER2.41BB CAR.
[0362] Components of the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex deubiquitination module, ATXN7L3 and USP22, were identified as the two most enriched hits across two donors. ATXN7L3 or USP22 KO (ATXKO / USPKO) CAR T cells have increased H2B ubiquitination and sustained expression of activation and early differentiation markers relative to control. Strikingly, ATXKO / USPKO CAR T cells persist and proliferate for months in in vitro cultures after a single stimulation. Conflictingly, however, ATXKO / USPKO CAR T cells do not improve in vivo antitumor immunity and have limited in vivo intratumoral persistence relative to control. Further analysis revealed that ATXKO / USPKO CAR T cells have a profound defect in IL-2 production, which likely contributes to their limited in vivo persistence. Restoration of IL-2 availability through CD8+-specific ATXKO CAR T paired with WT CD4+CAR T rescues in vivo tumor control, highlighting a dependency of ATXKO / USPKO CAR T cells on cell-extrinsic IL-2.
[0363] 61
[0364] 4897-8742-6199, V 1In sum, triple transduction of primary T cells with retro / lentiviruses permits high constitutive expression of CAR and CRISPR components. opCas12a is highly efficient in primary human T cells, with KO in over 90% of Cas+ / guide+cells. In vivo genome- wide Cas12a screen performed in CAR T cells using 30 tumor-bearing mice identified factors enhancing and regulating intratumoral CAR TIL persistence, including ATXN7L3 and USP22 as the top two hits. These findings generate new insight into the epigenetic regulation of human CAR T cells and establish a novel role for the SAGA complex and histone ubiquitination in regulating T cell biology.
[0365] Example 2
[0366] To validate the results of the genome-wide in vivo screen, the inventors first determined the in vitro effect of genetic knockout of ATXN7L3 and USP22 in human CAR T cells. These cells had significantly enhanced persistence and proliferation after single anti-CD3 / CD28 bead stim, regardless of CAR scFV or costimulation module. Further, ablation in primary human T cells similarly enhanced proliferation, indicating that ATXN7L3 and USP22 are T cell-intrinsic regulators of persistence. Follow-up in vitro immunophenotyping revealed an enhancement of T cell activation and memory genes with knockout. To further understand the alterations to CAR T cells upon loss of ATXN7L3 or USP22, the inventors performed bulk RNA sequencing. ATXN7L3 and USP22 knockout CAR T cells have an enhancement in MYC, mTOR, and E2F pathways, all associated with metabolically active and cycling T cells. Further, IL2 STAT5 signaling pathways were significantly altered with loss of either SAGA component. To further understand how the transcriptomic changes to this pathway relate to its functional activity, the inventors tested the proliferative response of CAR T cells to various doses of STAT5-directed cytokines. Under high doses of IL-2, IL-7, and IL- 15, USPKO / ATXKO CAR T cells had enhanced and persistent proliferation. Meanwhile, in low doses of IL-2, IL-7, and IL-15, under which control CAR T cells are minimally responsive, USPKO ATXKO CAR T cells had a substantial proliferative response.
[0367] Next, the inventors sought to validate USPKO / ATXKO CAR T cell performance in vivo. They first tested the 143b osteosarcoma solid tumor model used for the genome- wide screen. Unexpectedly, in multiple donors, USPKO / ATXKO CAR T cell performed worse than control CAR T at controlling osteosarcoma tumor volume. Further, when harvesting tumors to assess persistence, USPKO / ATXKO CAR T cell were substantially fewer in number than that of control, the opposite observation from that of our screen. The inventors hypothesized that 62
[0368] 4897-8742-6199, V 1USPKO / ATXKO alters the secretome of CAR T cells to limit their response. To assess secretory changes in an unbiased manner, they utilized a 36-plex cytokine array with the supernatant of stimulated CAR T cells. This revealed a substantial defect in IL-2 production by USPKO / ATXKO CAR T cells, a finding the inventors further validated across multiple CAR scFv and costimulatory domains. They next sought to rescue the diminished IL-2 production by engineering a ‘constitutive IL-2’ CAR T cell by adding a P2A linker followed by IL-2 after the HER2.41BBz CAR. After validating that these cells express IL-2 constitutively, the inventors again tested the 143b osteosarcoma tumor model in comparing control and ATXKO ‘constitutive IL-2’ CAR T cells and tracked circulating CAR T cell number. Impressively, ATXKO ‘constitutive IL-2’ CAR T cells had a substantial in vivo expansion, resulting in circulating T cell counts of 150,000 per pl of blood and orders of magnitude greater than that of control. This was accompanied by an enhanced anti-tumor response, but also substantial toxicity and weight loss to the mice bearing ATXKO ‘constitutive IL-2’ CAR T cells. In response, the inventors sought to finetune the activity of ATXKO by controlling the amount of exogenous IL-2 available with daily IL-2 injections. IL-2 injection again resulted with an enhancement in anti-tumor immunity, with only the ATXKO CAR T + IL-2 injection condition slowing tumor growth versus mock treated control. Although this was associated with weight loss, discontinuing IL-2 caused a rapid regain in weight and condition of mice. Collectively, these data demonstrate that USPKO / ATXKO CAR T cell activity can be controlled through exogenous cytokine, enabling a highly regulatable therapy to balance anti-tumor immunity and treatment toxicity.
[0369] * * * * * * * * * * * * * * * * *
[0370] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to
[0371] 63
[0372] 4897-8742-6199, V 1those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.
[0373] 64
[0374] 4897-8742-6199, V 1VI. References
[0375] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
[0376] U. S. Patent. 8,399,645
[0377] U. S. Patent 7,638,325
[0378] WO2017 / 096329
[0379] WO2000 / 14257
[0380] WO2013 / 126726
[0381] WO2012 / 129514
[0382] WO2014031687
[0383] WO2013 / 166321
[0384] WO2013 / 07115,
[0385] WO2013 / 123061
[0386] WO / 2014055668
[0387] U. S. Pat. Pub. No. US2002131960
[0388] U. S. Pat. Pub. No. US2013287748
[0389] U. S. Pat. Pub. No. US20130149337
[0390] U. S. Patent 6,451,995
[0391] U. S. Patent 7,446,190
[0392] U. S. Patent 7,638,325
[0393] U. S. Patent 8,252,592
[0394] U. S. Patent 8,339,645
[0395] U. S. Patent 8,398,282
[0396] U. S. Patent 7,446,179
[0397] U. S. Patent 6,410,319
[0398] U. S. Patent 7,070,995
[0399] U. S. Patent 7,265,209
[0400] U. S. Patent 7,354,762
[0401] 65
[0402] 4897-8742-6199, V 1U. S. Patent 7,446,191
[0403] U. S. Patent 8,324,353
[0404] U. S. Patent 8,479,118
[0405] U. S. Patent 4,873,316
[0406] European Pat. App. No. EP2537416
[0407] Kabat Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md. (1987 and 1991)
[0408] Bork et al., J Mol. Biol. 242, 309-320 (1994)
[0409] Chothia and Lesk J. Mol Biol. 196:901-917 (1987)
[0410] Chothia et al., Nature 342, 877-883 (1989)
[0411] Al-Lazikani etal., J Mol Biol 273, 927-948 (1997)
[0412] Kimura et al., Proteins 77(2):359-369, 2009)
[0413] U. S. Patent 9,913,878
[0414] McKeown S., Br. J. Radiol. 87(1035), 2014
[0415] Immunology - A Synthesis (2ndEdition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991))
[0416] " T cell Receptor Factsbook", (2001) LeFranc and LeFranc, Academic Press, ISBN 0-12- 441352-8
[0417] Sadelain et al. Cancer Discov. April 3(4): 388-398 (2013)
[0418] Davila etal. PLoS ONE 8(4): e61338 (2013)
[0419] Turtle et al. Curr. Opin. Immunol. October 24(5): 633-39 (2012)
[0420] Wu et al. Cancer, March 18(2): 160-75 (2012)
[0421] U. S. Serial No. 15 / 419,398
[0422] Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rded., Cold Spring Harbor Press, Cold Spring Harbor, N. Y. 2001
[0423] Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994.
[0424] Pinkert et al., Genes Dev. 1:268-277 (1987)
[0425] Calame et al., Adv. Immunol. 43:235-275 (1988)
[0426] Winoto et al., EMBO J. 8:729-733 (1989)
[0427] Baneiji et al., Cell 33:729-740 (1983)
[0428] 66
[0429] 4897-8742-6199, V 1Byrne et al., Proc. Natl. Acad. Sci. USA 86:5473-5477 (1989)
[0430] Edlunch et al., Science 230:912-916 (1985)
[0431] European Application Publication No. EP0264166
[0432] Enhancers and Eukaryotic Expression, Cold Spring Harbor Press, Cold Spring Harbor, N. Y.
[0433] 1983
[0434] Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990
[0435] Fedorov et al., Sci. Transl. Med. 2013 5(215):215
[0436] 67
[0437] 4897-8742-6199, V 1
Claims
WHAT IS CLAIMED:
1. A method of modifying a lymphocyte or lymphocyte population comprising:(a) providing a lymphocyte or lymphocyte population; and(b) modifying said lymphocyte or lymphocyte population to decrease or block expression of the gene products of (i) either or both the ATXN7L3 and / or USP22 genes, (ii) one or more of the other genes in FIG. 3E, and / or (iii) TADA1, SUPT20H, and / or TAF5L.
2. The method of claim 1, wherein modifying comprises gene editing of either or both ATXN7L3 and / or USP22 genes.
3. The method of claim 2, wherein gene editing comprises use of CRISPR, TALENs, or zinc-finger nucleases.
4. The method of any one of claims 1-3, wherein said lymphocyte or lymphocyte population is a T cell or T cell population.
5. The method of claim 4, wherein said T cell or T cell population is or comprises a regulatory T cell, a helper T cell, a cytotoxic T cell, a yδ T cell(s), an NK cell, a CAR T cell, a TCR-engineered T cell, a TIL or engineered TIL, an engineered version of any of the foregoing, or a population thereof.
6. The method of any one of claims 1-5, wherein only the USP22 gene or the ATXN7L3 is modified.
7. The method of any one of claims 1-5, wherein both the ATXN7L3 and USP22 genes are modified.
8. The method of any one of claims 1-7, wherein the selected lymphocyte or lymphocyte population are screened for the presence of one or both gene editing events.
9. The method of any one of claims 1-8, further expanding the lymphocyte or lymphocyte population after step (b).684897-8742-6199, V 110. The method of any one of claims 1-9, further comprising genetically modifying a lymphocyte or lymphocyte population to constitutively or inducibly express IL-2, IL-7 or IL- 15 or receptors for the same, or to express IL-2, IL-7 or IL- 15 or receptors for the same at a level greater than prior to modifying.
11. The method of any one of claims 1-9, further comprising genetically modifying a lymphocyte or lymphocyte population to inducibly express IL-2 or IL- 15 or receptors for the same, wherein IL-2 or IL- 15 expression or expression of receptors for the same is under the control of an T cell activation-associated promoter (e.g. NFKB promoter, NR4A promoter, NFAT promoter).
12. The method of any one of claims 1-9, further comprising genetically modifying a lymphocyte or lymphocyte population to inducibly express IL-2 or IL- 15 or receptors for the same, wherein IL-2 or IL- 15 expression or expression of or receptors for the same is under the control of a promoter in which its activity is controlled by a small molecule.
13. The method of any one of claims 1-9, further comprising genetically modifying a lymphocyte or lymphocyte population to inducibly signal, through an orthogonal IL-2 receptor or orthogonal IL- 15 receptor or receptors for the same, in response to an orthogonal IL-2 or IL- 15 cytokine.
14. The method of any one of claims 1-13, further comprising obtaining the lymphocyte or lymphocyte population prior to step (a).
15. The method of any one of claims 1-14, wherein modifying comprises gene editing (a) one or more of the other genes in FIG. 3E, and / or (b) TADA1, SUPT20H, and / or TAF5L.
16. A lymphocyte or lymphocyte population prepared according to the method of any one of claims 1-15.
17. A lymphocyte or population of lymphocytes comprising an impaired Spt-Ada-Gcn5 acetyltransferase (SAGA) complex deubiquitination module.694897-8742-6199, V 118. A lymphocyte or population of lymphocytes exhibiting increased H2B ubiquitination and sustained expression of activation and early differentiation markers.
19. A lymphocyte or population of lymphocytes comprising non-functional genes or genes that express functionally impaired (i) ATNX7L3 and / or USP22 gene products, (ii) one or more other gene products in FIG. 3E, and / or (iii) one or more TADA1, SUPT20H, and / or TAF5L gene products.
20. The lymphocyte or lymphocyte population of any one of claims 17-19, wherein the lymphocyte or lymphocytes is / are a T cell(s), such as a regulatory T cell(s), a yδ T cell(s), a helper T cell(s), a cytotoxic T cell(s), an NK cell(s), a CAR T cell(s), a TCR-engineered T cell, a TIL or engineered TIL.
21. A method of treating cancer comprising administering to a subject in need thereof a lymphocyte or lymphocyte population, wherein the lymphocyte or lymphocyte population is:(a) a lymphocyte or lymphocyte population produced according to the method of any one of claims 1-15: and / or(b) a lymphocyte of any one of claims 17-20.
22. A method of treating cancer comprising performing in vivo gene editing of a lymphocyte or lymphocyte population in subject in need thereof to generate nonfunctional genes or genes that express functionally impaired (i) ATNX7L3 and / or USP22 gene products, (ii) one or more other gene products in FIG. 3E, and / or (iii) one or more TADA1, SUPT20H, and / or TAF5L gene products.
23. The method of claim 21 or claim 22, further comprising administering a CD4+ lymphocyte or lymphocyte population to said subject.
24. The method of any one of claims 21-23, further comprising administering said CAR T cell and or said CD4+ lymphocyte or lymphocyte population more than one, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 times, or weekly, twice a month, once a month, every other month every three months, every six months, or annually.704897-8742-6199, V 125. The method of any one of claims 21-24, wherein the subject is mammal, such as a human.
26. The method of any one of claims 21-25, further comprising administering to said subject a radiotherapy, a chemotherapy, a second immunotherapy, or further performing a surgery.
27. The method of any one of claims 21-26, wherein the cancer is recurrent, metastatic or drug resistant.
28. The method of any one of claims 21-26, wherein the cancer is a renal cell cancer, melanoma, prostate cancer, bladder cancer, bone cancer, bone marrow cancer, brain cancer, breast cancer, colon cancer, esophageal cancer, gastrointestinal cancer, gum cancer, head & neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, stomach cancer, testicular cancer, oral cancer, uterine cancer, lymphoma, leukemia (CML, AML), or multiple myeloma.
29. The method of any one of claim 21-28, wherein said subject is administered IL-2 or IL- 15 via systemic administration or administration local or regional to a tumor or cancer site, such as wherein the lymphocyte is a TIL and / or the cancer is melanoma, and / or wherein the lymphocyte / TIL has a knock-out or disruption of one or more SAGA genes.
30. A method of treating cancer in a subject comprising administering a lymphocyte or lymphocyte population comprising inhibition of SAGA gene expression, in combination with mimicking of IL-2 or IL- 15 signaling, such as orthogonal IL-2 or IL- 15 systems, expression of synthetic cytokine receptors that signal constitutively or inducibly, or expression of STAT5 or other STAT transcription factors.
31. The method of claim 31, wherein inhibition of SAGA gene expression comprises a knock-out or disruption one or more SAGA genes, or dominant-negative inhibition of SAGA gene expression.714897-8742-6199, V 1
